documents incorporated reference portions abbvie inc proxy statement incorporated reference part iii definitive proxy statement filed march abbvie inc year ended december table contents part item business item risk factors item b unresolved staff comments item properties item legal proceedings item mine safety disclosures information executive officers part ii item market registrants common equity related stockholder matters issuer purchases equity securities item selected financial data item managements discussion analysis financial condition results operations item quantitative qualitative disclosures market risk item financial statements supplementary data item changes disagreements accountants accounting financial disclosure item controls procedures item b information part iii item directors executive officers corporate governance item executive compensation item security ownership certain beneficial owners management related stockholder matters item certain relationships related transactions director independence item principal accounting fees services part iv item exhibits financial statement schedules item summary signatures part item business overview abbvie global researchbased biopharmaceutical company abbvie develops markets advanced therapies address world 's complex serious diseases abbvie 's products focused treating conditions chronic autoimmune diseases rheumatology gastroenterology dermatology oncology including blood cancers virology including hepatitis c virus hcv human immunodeficiency virus hiv neurological disorders parkinson 's disease metabolic diseases including thyroid disease complications associated cystic fibrosis pain associated endometriosis well serious health conditions abbvie also pipeline promising new medicines clinical development across important medical specialties immunology oncology neuroscience additional targeted investment cystic fibrosis women 's health june abbvie announced entered definitive transaction agreement abbvie acquire allergan plc allergan allergan global pharmaceutical leader focused developing manufacturing commercializing branded pharmaceutical device biologic surgical regenerative medicine products patients around world allergan markets portfolio brands products primarily focused key therapeutic areas including aesthetics eye care neuroscience gastroenterology women 's health see note consolidated financial statements additional information regarding proposed acquisition abbvie incorporated delaware april january abbvie became independent publiclytraded company result distribution abbott laboratories abbott outstanding common stock abbvie abbott 's shareholders segments abbvie operates one business segmentpharmaceutical products see note consolidated financial statements sales information related humira imbruvica mavyret included item management 's discussion analysis financial condition results operations products abbvie 's portfolio products includes broad line therapies address world 's complex serious diseases immunology products abbvie maintains extensive immunology portfolio across rheumatology dermatology gastroenterology abbvie 's immunology products address unmet needs patients autoimmune diseases products humira humira adalimumab biologic therapy administered subcutaneous injection approved treat following autoimmune diseases united states canada mexico collectively north america european union condition principal markets rheumatoid arthritis moderate severe north america european union psoriatic arthritis north america european union ankylosing spondylitis north america european union adult crohn 's disease moderate severe north america european union plaque psoriasis moderate severe chronic north america european union juvenile idiopathic arthritis moderate severe polyarticular north america european union ulcerative colitis moderate severe north america european union axial spondyloarthropathy european union pediatric crohn 's disease moderate severe north america european union hidradenitis suppurativa moderate severe north america european union pediatric enthesitisrelated arthritis european union noninfectious intermediate posterior panuveitis north america european union used throughout text report terms abbvie company refer abbvie inc delaware corporation abbvie inc consolidated subsidiaries context requires humira also approved japan treatment intestinal behet 's disease humira sold numerous markets worldwide including japan china brazil australia accounted approximately abbvie 's total net revenues skyrizi skyrizi risankizumab interleukin il inhibitor selectively blocks il binding p subunit biologic therapy administered quarterly subcutaneous injection following induction dose skyrizi approved united states canada european union indicated treatment moderate severe plaque psoriasis adults candidates systemic therapy phototherapy japan skyrizi approved treatment plaque psoriasis generalized pustular psoriasis erythrodermic psoriasis psoriatic arthritis adult patients inadequate response conventional therapies rinvoq rinvoq upadacitinib oncedaily oral selective reversible jak inhibitor approved united states canada european union rinvoq indicated treatment moderate severe active rheumatoid arthritis adult patients responded inadequately intolerant one diseasemodifying antirheumatic drugs dmards rinvoq may used monotherapy combination methotrexate oncology products abbvies oncology products target complex difficulttotreat cancers products imbruvica imbruvica ibrutinib oral oncedaily therapy inhibits protein called bruton 's tyrosine kinase btk imbruvica one first medicines receive united states food drug administration fda approval granted breakthrough therapy designation one therapies receive four separate designations imbruvica currently approved treatment adult patients chronic lymphocytic leukemia cllsmall lymphocytic lymphoma sll cllsll p deletion mantle cell lymphoma mcl received least one prior therapy waldenstrms macroglobulinemia wm marginal zone lymphoma mzl require systemic therapy received least one prior anticdbased therapy chronic graft versus host disease cgvhd failure one lines systemic therapy accelerated approval granted indication based overall response rate continued approval indication may contingent upon verification clinical benefit confirmatory trials venclextavenclyxto venclexta venetoclax bcl inhibitor used treat hematological malignancies venclexta approved fda adults cll sll addition venclexta approved combination azacitidine decitabine lowdose cytarabine treat adults newlydiagnosed acute myeloid leukemia aml years age older medical conditions prevent use standard chemotherapy venclyxto approved europe cll combination rituximab patients received least one previous treatment virology products abbvie 's virology products address unmet needs patients living hcv hiv hcv products abbvie 's hcv products mavyretmaviret mavyret glecaprevirpibrentasvir approved united states european union maviret treatment patients chronic hcv genotype infection without cirrhosis compensated cirrhosis childpugh also indicated treatment adult patients hcv genotype infection previously treated regimen containing hcv nsa inhibitor nsa protease inhibitor week pangenotypic treatment patients without cirrhosis following expedition study also patients compensated cirrhosis new treatment maviret also indicated treatment hcv genotypes children years viekira pak technivie viekira pak ombitasvir paritaprevir ritonavir tablets dasabuvir tablets alloral shortcourse interferonfree therapy without ribavirin treatment adult patients genotype chronic hcv including compensated cirrhosis europe viekira pak marketed viekirax exviera approved use patients genotype genotype hcv abbvie 's technivie ombitasvir paritaprevir form kritonavir fdaapproved use combination ribavirin treatment adults genotype hcv infection united states use viekira united states europe japan currently limited given significant use pangenotypic regimens including maviret additional virology products abbvie 's additional virology products include synagis synagis palivizumab product marketed abbvie outside united states protects atrisk infants severe respiratory disease caused respiratory syncytial virus rsv kaletra kaletra lopinavirritonavir also marketed aluvia emerging markets prescription antihiv medicine contains two protease inhibitors lopinavir ritonavir kaletra used antihiv medications treatment maintains viral suppression people hiv metabolicshormones products metabolic hormone products target number conditions including testosterone deficiency due certain underlying conditions exocrine pancreatic insufficiency hypothyroidism products include creon creon pancrelipase pancreatic enzyme therapy exocrine pancreatic insufficiency condition occurs patients cystic fibrosis chronic pancreatitis several conditions synthroid synthroid levothyroxine sodium tablets usp used treatment hypothyroidism androgel androgel testosterone gel testosterone replacement therapy males diagnosed symptomatic low testosterone due certain underlying conditions abbvie rights sell androgel creon synthroid united states endocrinology products lupron leuprolide acetate also marketed lucrin lupron depot product palliative treatment advanced prostate cancer treatment endometriosis central precocious puberty preoperative treatment patients anemia caused uterine fibroids lupron approved daily subcutaneous injection onemonth threemonth fourmonth sixmonth intramuscular injection products abbvie 's products include orilissa orilissa elagolix first orallyadministered nonpeptide small molecule gonadotropinreleasing hormone gnrh antagonist specifically developed women moderate severe endometriosis pain fda approved orilissa priority review represents first fda approved oral treatment management moderate severe pain associated endometriosis decade orilissa inhibits endogenous gnrh signaling binding competitively gnrh receptors pituitary gland administration results dosedependent suppression luteinizing hormone folliclestimulating hormone leading decreased blood concentrations ovarian sex hormones estradiol progesterone outside united states orilissa also launched canada puerto rico duopa duodopa carbidopa levodopa abbvie 's levodopacarbidopa intestinal gel treatment advanced parkinson 's disease marketed duopa united states duodopa outside united states sevoflurane sevoflurane sold trademarks ultane sevorane anesthesia product abbvie sells worldwide human use marketing sales distribution capabilities abbvie utilizes combination dedicated commercial resources regional commercial resources distributorships market sell distribute products worldwide abbvie directs primary marketing efforts toward securing prescription recommendation brand products physicians key opinion leaders health care providers managed care providers example health maintenance organizations pharmacy benefit managers hospitals state federal government agencies example united states department veterans affairs united states department defense also important customers abbvie also markets directly consumers although united states company 's products must sold pursuant prescription outside united states abbvie focuses marketing efforts key opinion leaders payers physicians country regulatory bodies abbvie also provides patient support programs closely related products abbvie 's products generally sold worldwide directly wholesalers distributors government agencies health care facilities specialty pharmacies independent retailers abbvieowned distribution centers public warehouses although abbvie 's business significant seasonality abbvie 's product revenues may affected end customer retail buying patterns fluctuations wholesaler inventory levels factors united states abbvie distributes pharmaceutical products principally independent wholesale distributors sales directly pharmacies patients three wholesale distributors mckesson corporation cardinal health inc amerisourcebergen corporation accounted substantially abbvie 's sales united states individual wholesaler accounted greater abbvie 's gross revenues united states outside united states abbvie sells products primarily customers distributors depending market served wholesalers purchase product abbvie standard terms conditions sale certain products comarketed copromoted companies abbvie single customer customer lost would material adverse effect company 's business material portion abbvie 's business subject renegotiation profits termination contracts election government orders generally filled current basis order backlog material abbvie 's business competition markets abbvie 's products highly competitive abbvie competes researchbased pharmaceuticals biotechnology companies discover manufacture market sell proprietary pharmaceutical products biologics example humira competes antitnf products competitive products intended treat number disease states abbvie 's virology products compete available hcv treatment options search technological innovations pharmaceutical products significant aspect competition introduction new products competitors changes medical practices procedures result product obsolescence price also competitive factor addition substitution generic pharmaceutical products branded pharmaceutical products creates competitive pressures abbvie 's products patent protection new products treatments brought market abbvies competitors could cause revenues abbvies products decrease due price reductions sales volume decreases biosimilars competition abbvies biologic products affected approval followon biologics also known biosimilars biologics added major therapeutic options treatment many diseases including therapies unavailable inadequate cost developing producing biologic therapies typically dramatically higher conventional small molecule medications many biologic medications used ongoing treatment chronic diseases rheumatoid arthritis inflammatory bowel disease treatment previously untreatable cancer significant investments biologics infrastructure manufacturing necessary produce biologic products humira facing direct biosimilar competition europe countries abbvie continue face competitive pressure biologics orally administered products united states fda regulates biologics federal food drug cosmetic act public health service act implementing regulations enactment federal health care reform legislation march provided pathway approval biosimilars public health service act approval process science behind biosimilars complex approval fda dependent upon many factors including showing biosimilar highly similar original product clinically meaningful differences original product terms safety purity potency types data could ordinarily required application show similarity may include analytical data bioequivalence studies studies demonstrate chemical similarity animal studies including toxicity studies clinical studies furthermore law provides biosimilar product determined interchangeable considered substitutable original biologic product without intervention health care provider prescribed original biologic product prove biosimilar product interchangeable applicant must demonstrate product expected produce clinical results original biologic product given patient product administered patient safety risks potential diminished efficacy alternating switching use interchangeable biosimilar biologic product original biologic product greater risk using original biologic product without switching law continues interpreted implemented fda result ultimate impact implementation meaning remains subject substantial uncertainty intellectual property protection regulatory exclusivity generally upon approval products may entitled certain kinds exclusivity applicable intellectual property regulatory regimes abbvies intellectual property materially valuable company abbvie seeks patent protection available significant markets andor countries product development united states expiration date patents years filing date given patents relating pharmaceutical products often obtained early development process given amount time needed complete clinical trials development activities required regulatory approval length time product launch patent expiration significantly less years drug price competition patent term restoration act commonly known hatchwaxman act permits patent holder seek patent extension commonly called patent term restoration form kpatents products processes making product regulated federal food drug cosmetic act length patent extension roughly based percent period time filing investigational new drug application nda compound submission nda compound plus percent time period nda submission regulatory approval extension however exceed five years patent term remaining regulatory approval exceed years biological products licensed public health service act similarly eligible terms patent restoration pharmaceutical products may entitled forms legal regulatory exclusivity upon approval scope length requirements exclusivities vary united states jurisdictions united states fda approves drug product contains active ingredient previously approved product typically entitled five years nonpatent regulatory exclusivity products may entitled three years exclusivity approval based fdas reliance new clinical studies essential approval submitted nda applicant nda applicant studies product use children fda may grant pediatric exclusivity extends days existing exclusivities patent regulatory related product products either used treat conditions afflict relatively small population reasonable expectation research development costs recovered fda may designate pharmaceutical orphan drug grant seven years market exclusivity applicable laws regulations dictate scope exclusivity product particular characteristics product entitled upon approval particular country certain instances regulatory exclusivity may offer protection patent protection longer available period time excess patent protection possible estimate product development total period scope exclusivity may become entitled regulatory approval obtained however given length time required complete clinical development pharmaceutical product periods exclusivity might achieved individual case would expected exceed minimum three years maximum years estimates consider factors difficulty recreating manufacturing process particular product proprietary knowledge may delay introduction generic followon product expiration applicable patent regulatory exclusivity periods biologics may entitled exclusivity biologics price competition innovation act passed march title vii patient protection affordable care act law provides pathway approval biosimilars following expiration years regulatory exclusivity innovator biologic potential additional dayextension term conducting pediatric studies biologics also eligible orphan drug exclusivity discussed law also includes extensive process innovator biologic biosimilar manufacturer litigate patent infringement validity enforceability european union also created pathway approval biosimilars published guidelines approval certain biosimilar products complex nature biologics biosimilar products led close regulatory scrutiny followon biosimilar products reduce effect biosimilars sales innovator biologic compared sales erosion caused generic versions small molecule pharmaceutical products abbvie owns licensed rights substantial number patents patent applications abbvie licenses owns patent portfolio thousands patent families includes united states patent applications andor issued patents may also contain nonunited states counterparts patents applications patents applications including various patents expire period late aggregate believed material importance operation abbvies business however abbvie believes single patent license trademark related group patents licenses trademarks except related adalimumab sold trademark humira material relation companys business whole united states composition matter compound patent covering adalimumab expired december equivalent european union patent expired october majority european union countries united states noncomposition matter patents covering adalimumab expire earlier abbvie entered settlement license agreements several adalimumab biosimilar manufactures agreements license united states begin license europe began addition following patents licenses trademarks significant related ibrutinib sold trademark imbruvica related glecaprevir pibrentasvir sold trademarks mavyret maviret united states composition matter patent covering ibrutinib expected expire united states composition matter patents covering glecaprevir pibrentasvir expected expire abbvie may rely circumstances trade secrets protect technology however trade secrets difficult protect abbvie seeks protect technology product candidates part confidentiality agreements employees consultants advisors contractors collaborators agreements may breached abbvie may adequate remedies breach addition abbvies trade secrets may otherwise become known independently discovered competitors extent abbvies employees consultants advisors contractors collaborators use intellectual property owned others work company disputes may arise rights related resulting knowhow inventions licensing acquisitions arrangements addition independent efforts develop market products abbvie enters arrangements acquisitions optiontoacquire agreements licensing arrangements optiontolicense arrangements strategic alliances copromotion arrangements codevelopment comarketing agreements joint ventures acquisitions optiontoacquire agreements typically include among terms conditions nonrefundable purchase price payments option fees option exercise payments milestones earnouts customary terms obligations licensing arrangements typically include among terms conditions nonrefundable upfront license fees option fees option exercise payments milestone payments royalty andor profit sharing obligations see note licensing acquisitions arrangementsother licensing acquisitions activity consolidated financial statements included item financial statements supplementary data third party agreements abbvie agreements third parties process development product distribution analytical services manufacturing certain products abbvie procures certain products services limited number suppliers cases single supply source addition abbvie agreements third parties active pharmaceutical ingredient product manufacturing formulation development services fill finish packaging services transportation distribution logistics services certain products abbvie believe manufacturing related agreements material abbvie 's business substantially dependent individual agreement cases abbvie maintains alternate supply relationships utilize without undue disruption manufacturing processes third party fails perform contractual obligations abbvie also maintains sufficient inventory product minimize impact supply disruption abbvie also party certain collaborations arrangements discussed note licensing acquisitions arrangementsother licensing acquisitions activity consolidated financial statements included item financial statements supplementary data sources availability raw materials abbvie purchases ordinary course business raw materials supplies essential operations numerous suppliers around world addition certain medical devices components necessary manufacture abbvie products provided unaffiliated third party suppliers abbvie experienced recent significant availability problems supply shortages impacted fulfillment product demand research development activities abbvie makes significant investment research development numerous compounds clinical development including potential treatments complex lifethreatening diseases abbvie 's ability discover develop new compounds enhanced company 's use integrated discovery development project teams include chemists biologists physicians pharmacologists work compounds team abbvie also partners third parties biotechnology companies pharmaceutical companies academic institutions identify prioritize promising new treatments complement enhance abbvies existing portfolio research development process generally begins discovery research focuses identification molecule desired effect given disease preclinical testing identified compound proves successful compound moves clinical development generally includes following phases phase involves first human tests small number healthy volunteers patients assess safety tolerability potential dosing phase tests drug 's efficacy disease relatively small group patients phase tests drug demonstrates favorable results earlier phases significantly larger patient population demonstrate efficacy safety based regulatory criteria clinical trials development phases provide data required prepare submit nda biological license application bla submission regulatory approval fda similar government agencies outside united states specific requirements eg scope clinical trials obtaining regulatory approval vary across different countries geographic regions form kthe research development process discovery new drug launch typically takes years even longer research development new pharmaceutical products significant amount inherent uncertainty guarantee molecule receive regulatory approval required launch new drug indication addition development new products new formulations research development projects also may include phase trials sometimes called postmarketing studies projects clinical trials designed conducted collect additional data regarding among parameters benefits risks approved drug regulationdiscovery clinical development united states securing approval market new pharmaceutical product united states requires substantial effort financial resources takes several years complete applicant must complete preclinical tests submit protocols fda commencing clinical trials clinical trials intended establish safety efficacy pharmaceutical product typically conducted sequential phases although phases may overlap combined required clinical testing successful results submitted fda form nda bla requesting approval market product one indications fda reviews nda bla determine whether product safe effective intended use whether manufacturing compliant current good manufacturing practices cgmp even nda bla receives approval applicant must comply postapproval requirements example holders approval must report adverse reactions provide updated safety efficacy information comply requirements concerning advertising promotional materials activities also quality control manufacturing procedures must continue conform cgmp approval certain changes manufacturing procedures finished product must included nda bla approved fda prior implementation fda periodically inspects manufacturing facilities assess compliance cgmp imposes extensive procedural record keeping requirements addition condition approval fda may require postmarketing testing surveillance assess monitor product 's safety efficacy commercialization may require additional clinical trials patient registries observational data additional work chemistry manufacturing controls post approval regulatory obligations cost complying obligations could expand future outside united states abbvie subject similar regulatory requirements outside united states approval marketing pharmaceutical products abbvie must obtain approval clinical trial application product applicable regulatory authorities commence clinical trials marketing product approval requirements process country vary time required obtain approval may longer shorter required fda approval united states example abbvie may submit marketing authorizations european union either centralized decentralized procedure centralized procedure mandatory approval biotechnology products many pharmaceutical products provides single marketing authorization valid european union member states centralized procedure single marketing authorization application submitted european medicines agency ema agency evaluates application makes recommendation european commission makes final determination whether approve application decentralized procedure provides mutual recognition individual national approval decisions available products subject centralized procedure japan applications approval new product made pharmaceutical medical devices agency pmda bridging studies demonstrate nonjapanese clinical data applies japanese patients may required completing comprehensive review pmda reports ministry health labour welfare approves denies application regulatory process many emerging markets continues evolve many emerging markets including asia generally require regulatory approval obtained large developed market united states europe country begin complete regulatory review process countries also require local clinical studies conducted order obtain regulatory approval country requirements governing conduct clinical trials product licensing also vary addition postapproval regulatory obligations adverse event reporting cgmp compliance generally apply may vary country example marketing authorization granted european union periodic safety reports must submitted pharmacovigilance measures may required risk management plans regulationcommercialization distribution manufacturing manufacture marketing sale promotion distribution abbvie 's products subject comprehensive government regulation government regulation various national regional federal state local agencies united states countries addresses among matters inspection controls research laboratory procedures clinical investigations product approvals manufacturing labeling packaging marketing promotion pricing reimbursement sampling distribution quality control postmarketing surveillance record keeping storage disposal practices abbvie 's operations also affected trade regulations many countries limit import raw materials finished products laws regulations seek prevent corruption bribery marketplace including united states foreign corrupt practices act united kingdom bribery act provide guidance corporate interactions government officials require safeguards protection personal data addition abbvie subject laws regulations pertaining health care fraud abuse including state federal antikickback false claims laws united states prescription drug manufacturers abbvie also subject taxes well application product user fees compliance laws regulations costly materially affects abbvie 's business among effects health care regulations substantially increase time difficulty costs incurred obtaining maintaining approval market newly developed existing products abbvie expects compliance regulations continue require significant technical expertise capital investment ensure compliance failure comply delay release new product result regulatory enforcement actions seizure recall product suspension revocation authority necessary product 's production sale civil criminal sanctions including fines penalties addition regulatory initiatives abbvie 's business affected ongoing studies utilization safety efficacy outcomes health care products components regularly conducted industry participants government agencies others studies call question utilization safety efficacy previously marketed products cases studies resulted may future result discontinuance limitations marketing products domestically worldwide may give rise claims damages persons believe injured result use access human health care products continues subject oversight investigation action governmental agencies legislative bodies private organizations united states countries major focus cost containment efforts reduce health care costs also made private sector notably health care payers providers instituted various cost reduction containment measures abbvie expects insurers providers continue attempts reduce cost health care products outside united states many countries control price health care products directly indirectly reimbursement payment pricing coverage limitations compulsory licensing political budgetary pressures united states countries may also heighten scope severity pricing pressures abbvie 's products foreseeable future united states specifically us federal laws require pharmaceutical manufacturers pay certain statutorilyprescribed rebates state medicaid programs prescription drugs reimbursed state medicaid plans efforts states seek additional rebates affect abbvie 's business similarly veterans health care act prerequisite participation medicaid federal health care programs requires manufacturers extend additional discounts pharmaceutical products various federal agencies including united states department veterans affairs department defense public health service entities institutions addition recent legislative changes would require similarly discounted prices offered tricare program beneficiaries veterans health care act also established b drug discount program requires pharmaceutical manufacturers provide products reduced prices various designated health care entities facilities united states states also generic substitution legislation requiring permitting dispensing pharmacist substitute different manufacturer 's generic version pharmaceutical product one prescribed addition federal government follows diagnosisrelated group drg payment system certain institutional services provided medicare medicaid implemented prospective payment system pps services delivered hospital outpatient nursing home home health settings drg pps entitle health care facility fixed reimbursement based diagnosis andor procedure rather actual costs incurred patient treatment thereby increasing incentive facility limit control expenditures many health care products medicare reimburses part b drugs based average sales price plus certain percentage account physician administration costs reduced hospital outpatient setting medicare enters contracts private plans negotiate prices patientadministered medicine delivered part patient protection affordable care act health care education reconciliation act together affordable care act abbvie pays fee related pharmaceuticals sales government programs addition abbvie provides discount branded prescription drugs sold patients fall medicare part coverage gap donut hole affordable care act also includes provisions known physician payments sunshine act require manufacturers drugs biologics covered medicare medicaid record transfers value physicians form kteaching hospitals report data centers medicare medicaid services subsequent public disclosure similar reporting requirements also enacted state level united states increasing number countries worldwide either adopted considering similar laws requiring disclosure interactions health care professionals failure report appropriate data may result civil criminal fines andor penalties abbvie expects debate continue government levels worldwide marketing availability method delivery payment health care products services abbvie believes future legislation regulation markets serves could affect access health care products services increase rebates reduce prices rate price increases health care products services change health care delivery systems create new fees obligations pharmaceuticals industry require additional reporting disclosure possible predict extent abbvie health care industry general might affected matters discussed european union european union adopted directives legislation governing labeling advertising distribution supply pharmacovigilance marketing pharmaceutical products legislation provides mandatory standards throughout european union permits member states supplement standards additional regulations european governments also regulate pharmaceutical product prices control national health care systems fund large part cost products consumers result patients unlikely use pharmaceutical product reimbursed government many european countries government either regulates pricing new product launch subsequent launch direct price controls reference pricing recent years many countries also imposed new additional cost containment measures pharmaceutical products differences national pricing regimes create price differentials within european union lead significant parallel trade pharmaceutical products governments also promote generic substitution mandating permitting pharmacist substitute different manufacturer 's generic version pharmaceutical product one prescribed permitting mandating health care professionals prescribe generic versions certain circumstances many governments also following similar path biosimilar therapies addition governments use reimbursement lists limit pharmaceutical products eligible reimbursement national health care systems japan japan national health insurance system maintains drug price list specifying pharmaceutical products eligible reimbursement ministry health labour welfare sets prices products list government generally introduces price cut rounds every year also mandates price decreases specific products new products judged innovative useful indicated pediatric use target orphan small population diseases however may eligible pricing premium government also promoted use generics available emerging markets many emerging markets take steps reduce pharmaceutical product prices cases direct price controls others promotion genericbiosimilar alternatives branded pharmaceuticals since abbvie markets products worldwide certain products local nature variations product lines must also meet local regulatory requirements certain additional risks inherent conducting business outside united states including price currency exchange controls changes currency exchange rates limitations participation local enterprises expropriation nationalization governmental action environmental matters abbvie believes operations comply material respects applicable laws regulations concerning environmental protection regulations federal state environmental laws impose stringent limitations emissions discharges environment various manufacturing operations abbvie 's capital expenditures pollution control approximately million operating expenditures approximately million capital expenditures pollution control estimated approximately million operating expenditures estimated approximately million abbott identified one many potentially responsible parties investigations andor remediations several locations united states including puerto rico comprehensive environmental response compensation liability act commonly known superfund locations transferred abbvie connection separation distribution abbvie become party investigations remediations abbott also engaged remediation several sites transferred abbvie connection separation distribution cooperation environmental protection agency similar agencies feasible predict certainty final costs related investigations remediation activities abbvie believes costs together expenditures maintain compliance applicable laws regulations concerning environmental protection material adverse effect company 's financial position cash flows results operations employees abbvie employed approximately persons january outside united states abbvie 's employees represented unions works councils abbvie believes good relations employees internet information copies abbvie 's annual reports quarterly reports form q current reports form k amendments reports filed furnished pursuant section securities exchange act available free charge abbvie 's investor relations website wwwabbvieinvestorcom soon reasonably practicable abbvie electronically files material furnishes securities exchange commission sec abbvie 's corporate governance guidelines outline directorship qualifications code business conduct charters abbvie 's audit committee compensation committee nominations governance committee public policy committee available abbvie 's investor relations website wwwabbvieinvestorcom item risk factors carefully consider following risks information evaluating abbvie abbvie 's common stock following risks could materially adversely affect abbvie 's results operations financial condition cash flows risk factors generally separated three groups risks related abbvie 's business risks related abbvie 's proposed acquisition allergan acquisition combined company upon completion acquisition risks related abbvie 's common stock based information currently known abbvie believes following information identifies significant risk factors affecting categories risks however risks uncertainties abbvie faces limited set forth risk factors described may order importance probability occurrence additional risks uncertainties presently known abbvie abbvie currently believes immaterial may also adversely affect business addition past financial performance may reliable indicator future performance historical trends used anticipate results trends future periods following risks uncertainties develops actual events events could material adverse effect abbvie 's business results operations financial condition cash flows case trading price abbvie 's common stock could decline risks related abbvie 's business expiration loss patent protection licenses may adversely affect abbvie 's future revenues operating earnings abbvie relies patent trademark intellectual property protection discovery development manufacturing sale products particular patent protection aggregate important abbvie 's marketing pharmaceutical products united states major markets outside united states patents covering abbvie products normally provide market exclusivity important profitability many abbvie 's products patents certain products expire abbvie could face competition lower priced generic biosimilar products expiration loss patent protection product typically followed promptly substitutes may significantly reduce sales product short amount time abbvie 's competitive position compromised generics biosimilars otherwise could material adverse effect abbvie 's business results operations addition proposals emerge time time legislation encourage early rapid approval generic drugs biosimilars proposals enacted law could increase impact generic competition abbvie 's principal patents trademarks described greater detail item businessintellectual property protection regulatory exclusivity item management 's discussion analysis financial condition results operationsresults operations litigation regarding patents described item legal proceedings united states composition matter patent humira abbvie 's largest product worldwide net revenues approximately billion expired december equivalent european union patent expired majority european union countries october form kabbvie 's major products could lose patent protection earlier expected could adversely affect abbvie 's future revenues operating earnings third parties government authorities may challenge seek invalidate circumvent abbvie 's patents patent applications example manufacturers generic pharmaceutical products file may continue file abbreviated new drug applications fda seeking market generic forms abbvie 's products prior expiration relevant patents owned licensed abbvie asserting patents invalid unenforceable andor infringed addition petitioners filed may continue file challenges validity abbvie patents leahysmith america invents act created inter partes review post grant review procedures challenging patent validity administrative proceedings united states patent trademark office although challenges abbvie 's intellectual property come businesses governments may also challenge intellectual property rights example court decisions potential legislation relating patents legislation regarding biosimilars regulatory initiatives may result erosion intellectual property protection addition certain governments outside united states indicated compulsory licenses patents may sought domestic policies basis national emergencies hivaids triggered compulsory licenses could diminish eliminate sales profits jurisdictions negatively affect abbvie 's results operations abbvie normally responds challenges vigorously defending patents including filing patent infringement lawsuits patent litigation administrative proceedings challenges abbvie 's patents costly unpredictable may deprive abbvie market exclusivity patented product extent abbvie 's intellectual property successfully challenged circumvented weakened extent intellectual property allow abbvie compete effectively abbvie 's business suffer extent countries enforce abbvie 's intellectual property rights require compulsory licensing abbvie 's intellectual property abbvie 's future revenues operating earnings reduced third party 's intellectual property may prevent abbvie selling products material adverse effect abbvie 's future profitability financial condition third parties may claim abbvie product infringes upon intellectual property resolving intellectual property infringement claim costly time consuming may require abbvie enter license agreements abbvie guarantee would able obtain license agreements commercially reasonable terms successful claim patent intellectual property infringement could subject abbvie significant damages injunction preventing manufacture sale use affected abbvie product products events could material adverse effect abbvie 's profitability financial condition significant event adversely affects humira revenues could material negative impact abbvie 's results operations cash flows humira accounted approximately abbvie 's total net revenues significant event adversely affects humira 's revenues could material adverse impact abbvie 's results operations cash flows events could include loss patent protection humira described expiration loss patent protection licenses may adversely affect abbvies future revenues operating earnings commercialization biosimilars humira discovery previously unknown side effects impaired efficacy increased competition introduction new effective less expensive treatments discontinuation removal market humira reason abbvie 's research development efforts may succeed developing marketing commercially successful products technologies may cause revenues profitability decline remain competitive abbvie must continue launch new products new indications andor brand extensions existing products launches must generate revenue sufficient cover substantial research development costs replace revenues profitable products lost displaced competing products therapies failure would material adverse effect abbvie 's revenue profitability accordingly abbvie commits substantial effort funds resources research development must make ongoing substantial expenditures without assurance efforts commercially successful high rate failure biopharmaceutical industry inherent research development new products failure occur point research development process including significant funds invested products appear promising development may fail reach market numerous reasons including failure demonstrate effectiveness safety concerns superior safety efficacy competing therapies failure achieve positive clinical pre clinical outcomes beyond current standards care inability obtain necessary regulatory approvals delays approval new products new indications limited scope approved uses excessive costs manufacture failure obtain maintain intellectual property rights infringement intellectual property rights others decisions research studies made early development process pharmaceutical product candidate affect marketing strategy candidate receives approval detailed studies may demonstrate additional benefits help marketing also consume time resources may delay submitting pharmaceutical product candidate approval abbvie guarantee proper balance speed testing made respect pharmaceutical product candidate decisions area would adversely affect abbvie 's future results operations even abbvie successfully develops markets new products enhancements existing products may quickly rendered obsolete changing clinical preferences changing industry standards competitors ' innovations abbvie 's innovations may accepted quickly marketplace existing clinical practices uncertainty thirdparty reimbursement abbvie state certainty whether products development launched whether able develop license otherwise acquire compounds products whether products commercially successful failure launch successful new products new indications existing products may cause abbvie 's products become obsolete causing abbvie 's revenues operating results suffer portion abbvie 's nearterm pharmaceutical pipeline relies collaborations third parties may adversely affect development sale products abbvie depends alliances pharmaceutical biotechnology companies portion products nearterm pharmaceutical pipeline failures parties meet contractual regulatory obligations abbvie disruption relationships abbvie third parties could adverse effect abbvie 's pharmaceutical pipeline business addition abbvie 's collaborative relationships research development extend many years may give rise disputes regarding relative rights obligations revenues abbvie collaboration partners including ownership intellectual property associated rights obligations could result loss intellectual property rights protection delay development sale potential pharmaceutical products lead lengthy expensive litigation administrative proceedings arbitration biologics carry unique risks uncertainties could negative impact future results operations successful discovery development manufacturing sale biologics long expensive uncertain process unique risks uncertainties biologics example access supply necessary biological materials cell lines may limited governmental regulations restrict access regulate transport use materials addition development manufacturing sale biologics subject regulations often complex extensive regulations applicable pharmaceutical products manufacturing biologics especially large quantities often complex may require use innovative technologies manufacturing also requires facilities specifically designed validated purpose sophisticated quality assurance quality control procedures biologics also frequently costly manufacture production inputs derived living animal plant material biologics made synthetically failure successfully discover develop manufacture sell biologicsincluding humiracould adversely impact abbvie 's business results operations abbvie 's biologic products subject competition biosimilars biologics price competition innovation act creates framework approval biosimilars united states could allow competitors reference data biologic products already approved europe european commission granted marketing authorizations several biosimilars pursuant set general product classspecific guidelines biosimilar approvals issued past years addition companies developing biosimilars countries could compete abbvies biologic products including humira competitors obtain marketing approval biosimilars referencing abbvies biologic products abbvies products may become subject competition biosimilars attendant competitive pressure consequences expiration successful challenge abbvies applicable patent rights could also trigger competition products assuming relevant form kexclusivity period expired result abbvie could face litigation administrative proceedings respect validity andor scope patents relating biologic products new products technological advances abbvie 's competitors may negatively affect abbvie 's results operations abbvie competes researchbased pharmaceutical biotechnology companies discover manufacture market sell proprietary pharmaceutical products biologics example humira competes antitnf products competitive products intended treat number disease states abbvies virology products compete available hepatitis c treatment options competitors may introduce new products develop technological advances compete abbvies products therapeutic areas immunology virologyliver disease oncology neuroscience abbvie predict certainty timing impact introduction competitors new products technological advances competing products may safer effective effectively marketed sold lower prices superior performance features abbvies products could negatively impact abbvies business results operations manufacture many abbvie 's products highly exacting complex process abbvie one suppliers encounters problems manufacturing abbvie 's products abbvie 's business could suffer manufacture many abbvie 's products highly exacting complex process due part strict regulatory requirements problems may arise manufacturing variety reasons including equipment malfunction failure follow specific protocols procedures problems raw materials delays related construction new facilities expansion existing facilities including intended support future demand abbvie 's products changes manufacturing production sites limits manufacturing capacity due regulatory requirements changes types products produced physical limitations could inhibit continuous supply manmade natural disasters environmental factors problems arise production batch product batch product may discarded abbvie may experience product shortages incur added expenses could among things lead increased costs lost revenue damage customer relations time expense spent investigating cause depending cause similar losses respect batches products problems discovered product released market recall product liability costs may also incurred abbvie uses number products pharmaceutical biologic manufacturing processes sourced single suppliers interruption supply products could adversely affect abbvie 's business results operations abbvie uses number products pharmaceutical biologic manufacturing processes sourced single suppliers failure singlesource suppliers fulfill contractual obligations timely manner result regulatory noncompliance physical disruption manufacturing site may impair abbvie 's ability deliver products customers timely competitive basis could adversely affect abbvie 's business results operations finding alternative supplier could take significant amount time involve significant expense due nature products need obtain regulatory approvals abbvie guarantee able reach agreement alternative providers regulatory authorities would approve abbvie 's use alternatives abbvie however carry business interruption insurance provides degree protection case failure singlesource supplier significant safety efficacy issues could arise abbvie 's products could material adverse effect abbvie 's revenues financial condition pharmaceutical products receive regulatory approval based data obtained controlled clinical trials limited duration following regulatory approval products used longer periods time many patients investigators may also conduct additional perhaps extensive studies new safety efficacy issues reported new scientific information becomes available including results postmarketing phase trials governments change standards regarding safety efficacy labeling abbvie may required amend conditions use product example abbvie may voluntarily provide required provide updated information product 's label narrow approved indication either could reduce product 's market acceptance safety efficacy issues abbvie product arise sales product could halted abbvie regulatory authorities regulatory action could taken regulatory authorities safety efficacy issues affecting suppliers ' competitors ' products also may reduce market acceptance abbvie 's products new data abbvie 's products products similar products could negatively impact demand abbvie 's products due real perceived safety issues uncertainty regarding efficacy cases could result product withdrawal furthermore new data information including information product misuse may lead government agencies professional societies practice management groups organizations involved various diseases publish guidelines recommendations related use abbvie 's products use related therapies place restrictions sales guidelines recommendations may lead lower sales abbvie 's products abbvie subject product liability claims lawsuits may adversely affect business results operations ordinary course business abbvie subject product liability claims lawsuits alleging abbvie 's products products companies promotes resulted could result unsafe condition injury patients product liability claims lawsuits safety alerts product recalls regardless ultimate outcome may material adverse effect abbvie 's business results operations reputation ability attract retain customers consequences may also include additional costs decrease market share product question lower income exposure claims product liability losses selfinsured abbvie also subject claims legal proceedings investigations ordinary course business relate intellectual property commercial securities matters adverse outcomes claims legal proceedings investigations may also adversely affect abbvies business results operations abbvie subject costcontainment efforts pricing pressures could cause reduction future revenues operating earnings changes terms rebate chargeback programs common pharmaceuticals industry could material adverse effect abbvie 's operations costcontainment efforts governments private organizations described greater detail item businessregulationcommercialization distribution manufacturing extent cost containment efforts offset greater demand increased patient access health care factors abbvie 's future revenues operating earnings reduced united states european union countries abbvie 's business experienced downward pressure product pricing pressure could increase future abbvie subject increasing public legislative pressure respect pharmaceutical pricing united states practices managed care groups institutional governmental purchasers united states federal laws regulations related medicare medicaid including medicare prescription drug improvement modernization act patient protection affordable care act contribute pricing pressures potential continuing changes health care system united states increased purchasing power entities negotiate behalf medicare medicaid private sector beneficiaries could result additional pricing pressures numerous major markets worldwide government plays significant role funding health care services determining pricing reimbursement pharmaceutical products consequently markets abbvie subject government decisionmaking budgetary actions respect products particular many european countries ongoing governmentmandated price reductions many pharmaceutical products abbvie anticipates continuing pricing pressures europe differences countries pricing regulations could lead thirdparty crossborder trading abbvie 's products results reduction future revenues operating earnings rebates related government programs feeforservice medicaid medicaid managed care programs arise laws regulations abbvie predict additional government initiatives contain health care costs factors could lead new modified regulatory requirements include higher incremental rebates discounts rebate discount programs arise contractual agreements private payers various factors including market factors ability private payers control patient access products may provide payers leverage negotiate higher additional rebates discounts could material adverse effect abbvie 's operations form kabbvie subject numerous governmental regulations costly comply regulations develop compliant products processes abbvie 's products subject rigorous regulation numerous international supranational federal state authorities described item businessregulationdiscovery clinical development process obtaining regulatory approvals market pharmaceutical product costly time consuming approvals might granted future products additional indications uses existing products timely basis delays receipt failure obtain approvals future products new indications uses could result delayed realization product revenues reduction revenues substantial additional costs addition abbvie guarantee remain compliant applicable regulatory requirements approval obtained product requirements include among things regulations regarding manufacturing practices product labeling advertising postmarketing reporting including adverse event reports field alerts due manufacturing quality concerns abbvie must incur expense spend time effort ensure compliance complex regulations possible regulatory actions could result substantial modifications abbvie 's business practices operations refunds recalls seizures abbvie 's products total partial shutdown production one abbvie 's suppliers ' facilities abbvie supplier remedies alleged violation inability obtain future approvals withdrawals suspensions current products market events could disrupt abbvie 's business material adverse effect business results operations laws regulations affecting government benefit programs could impose new obligations abbvie require change business practices restrict operations future health care industry subject various federal state international laws regulations pertaining government benefit programs reimbursement rebates price reporting regulation health care fraud abuse united states laws include antikickback false claims laws medicaid rebate statute veterans health care act individual state laws relating pricing sales marketing practices violations laws may punishable criminal andor civil sanctions including instances substantial fines imprisonment exclusion participation federal state health care programs including medicare medicaid veterans administration health programs laws regulations broad scope subject change evolving interpretations could require abbvie incur substantial costs associated compliance alter one sales marketing practices addition violations laws allegations violations could disrupt abbvie 's business result material adverse effect business results operations international nature abbvie 's business subjects additional business risks may cause revenue profitability decline abbvie 's business subject risks associated business internationally including emerging markets net revenues outside united states made approximately abbvie 's total net revenues risks associated abbvie 's operations outside united states include fluctuations currency exchange rates changes medical reimbursement policies programs multiple legal regulatory requirements subject change could restrict abbvie 's ability manufacture market sell products differing local product preferences product requirements trade protection measures import export licensing requirements international trade disruptions disputes including connection ongoing trade negotiations united states china difficulty establishing staffing managing operations differing labor regulations potentially negative consequences changes interpretations tax laws political economic instability including united kingdoms exit european union sovereign debt issues price currency exchange controls limitations participation local enterprises expropriation nationalization governmental action inflation recession fluctuations interest rates potential deterioration economic position credit quality certain nonus countries including europe latin america potential penalties adverse consequences violations anticorruption antibribery similar laws regulations including united states foreign corrupt practices act united kingdom bribery act events contemplated risks may individually aggregate material adverse effect abbvie 's revenues profitability abbvie effectively profitably commercialize products abbvie 's revenues financial condition could adversely affected abbvie must effectively profitably commercialize principal products creating meeting continued market demand achieving market acceptance generating product sales ensuring active pharmaceutical ingredients product finished product manufactured sufficient quantities compliance requirements fda similar foreign regulatory agencies acceptable quality pricing meet commercial demand ensuring entire supply chain efficiently consistently delivers abbvie 's products customers commercialization abbvie products may successful due among things unexpected challenges competitors new safety issues concerns reported may impact narrow approved indications relative price abbvie 's product compared alternative treatment options changes product 's label restrict marketing commercialization abbvie 's principal products unsuccessful abbvie 's ability generate revenue product sales adversely affected abbvie may acquire businesses license rights technologies products form alliances dispose assets could cause incur significant expenses could negatively affect profitability abbvie may pursue acquisitions pending acquisition allergan technology licensing arrangements strategic alliances dispose assets part business strategy abbvie may complete transactions timely manner costeffective basis may realize expected benefits abbvie successful making acquisition products technologies acquired may successful may require significantly greater resources investments originally anticipated abbvie may able integrate acquisitions successfully existing business could incur assume significant debt unknown contingent liabilities abbvie could also experience negative effects reported results operations acquisition dispositionrelated charges amortization expenses related intangibles charges impairment longterm assets effects could cause deterioration abbvie 's credit rating result increased borrowing costs interest expense additionally changes abbvie 's structure operations revenues costs efficiency resulting major transactions acquisitions divestitures mergers alliances restructurings strategic initiatives may result greater expected costs may take longer expected complete encounter difficulties including need regulatory approval appropriate abbvie dependent wholesale distributors distribution products united states accordingly results operations could adversely affected encounter financial difficulties three wholesale distributors mckesson corporation cardinal health inc amerisourcebergen corporation accounted substantially abbvie 's sales united states one significant wholesale distributors encounters financial difficulties distributor may decrease amount business abbvie abbvie may unable collect amounts distributor owes timely basis could negatively impact abbvie 's business results operations form kabbvie debt obligations could adversely affect business ability meet obligations amount debt abbvie incurred intends incur could important consequences abbvie investors consequences include among things requiring portion abbvie 's cash flow operations make interest payments debt reducing cash flow available fund capital expenditures corporate purposes grow abbvie 's business extent abbvie incurs additional indebtedness interest rates increase risks could increase addition abbvie 's cash flow operations may sufficient repay outstanding debt becomes due abbvie may able borrow money sell assets otherwise raise funds acceptable terms refinance debt abbvie may need additional financing future meet capital needs make opportunistic acquisitions financing may available favorable terms abbvie may need seek additional financing general corporate purposes example may need increase investment research development activities need funds make acquisitions abbvie may unable obtain desired additional financing terms favorable abbvie loses investment grade credit rating adequate funds available acceptable terms abbvie may unable fund expansion successfully develop enhance products respond competitive pressures could negatively affect abbvie 's business abbvie raises additional funds issuing debt entering credit facilities may subject limitations operations due restrictive covenants failure comply covenants could adversely affect abbvie 's business abbvie depends information technology failure systems could adversely affect abbvie 's business abbvie relies sophisticated software applications complex information technology systems operate business systems potentially vulnerable malicious intrusion random attack loss data privacy disruption degradation breakdown data privacy security breaches employees others may result failure critical business operations may cause sensitive data including intellectual property trade secrets personal information belonging abbvie patients customers business partners exposed unauthorized persons public although abbvie invested protection data information technology also monitors systems ongoing basis assurance efforts prevent breakdowns breaches abbvie 's information technology systems could adversely affect abbvie 's business adverse consequences could include loss revenue loss critical sensitive information abbvies thirdparty providers databases systems could also result legal financial reputational business harm abbvie potentially substantial remediation costs failure attract retain highly qualified personnel could affect abbvies ability successfully develop commercialize products abbvies success largely dependent continued ability attract retain highly qualified scientific technical management personnel well personnel expertise clinical rd governmental regulation commercialization competition qualified personnel biopharmaceutical field intense abbvie sure able attract retain quality personnel costs materially increase factors material adverse effect abbvie 's profitability financial condition many factors affect abbvie 's results operations cash flows financial condition including changes interpretations laws regulations including changes accounting standards taxation requirements product marketing application standards data privacy laws environmental laws differences fair value measurement assets liabilities actual value particularly pension postemployment benefits stockbased compensation intangibles goodwill contingent liabilities litigation contingent consideration absence recorded amount amount recorded minimum compared actual amount changes rate inflation including cost raw materials commodities supplies interest rates market value abbvie 's equity investments performance investments held employee benefit trusts changes creditworthiness counterparties transact business provide services abbvie employee benefit trusts changes ability third parties provide information technology accounting human resources payroll outsourced services abbvie meet contractual obligations abbvie changes business economic political conditions including war political instability terrorist attacks threat future terrorist activity related military action natural disasters cost availability insurance due foregoing events labor disputes strikes slowdowns forms labor union activity pressure thirdparty interest groups risks related acquisition combined company upon completion acquisition pending acquisition allergan may completed currently contemplated timeline terms may achieve intended benefits consummation acquisition conditioned among things obtaining necessary governmental regulatory approvals conditions acquisition satisfied could delay prevent acquisition occurring could negatively impact abbvies share price future business financial results condition approval acquisition agencies may impose requirements limitations costs require divestitures place restrictions conduct abbvies business closing requirements limitations costs divestitures restrictions could jeopardize delay consummation acquisition may reduce anticipated benefits transaction addition changes laws regulations including irish legislation implementing tax increase payable upon completion acquisition could adversely impact abbvies postacquisition profitability financial results following acquisition abbvie may realize acquisitions intended benefits within expected timeframe indebtedness combined company following consummation acquisition substantially greater abbvies indebtedness standalone basis greater combined indebtedness abbvie allergan prior announcement acquisition increased level indebtedness could adversely affect combined companys business flexibility increase borrowing costs abbvie expects cash consideration due allergans shareholders transaction agreement related fees expenses approximately billion addition using cash hand abbvie incurred significant acquisitionrelated debt financing including unsecured term loans senior notes information see note debt credit facilities commitments contingencies consolidated financial statements included item financial statements supplementary data abbvie also intends assume existing indebtedness allergan subsidiaries abbvies substantially increased indebtedness higher debt equity ratio following consummation acquisition may effect among things reducing flexibility respond changing business economic conditions lowering credit ratings increasing borrowing costs andor requiring reduce delay investments strategic acquisitions capital expenditures seek additional capital restructure refinance indebtedness risks related abbvie 's common stock abbvie guarantee timing amount payment dividends common stock although abbvie expects pay regular cash dividends timing declaration amount payment future dividends stockholders fall within discretion abbvie 's board directors board 's decisions regarding payment dividends depend many factors abbvie 's financial condition earnings capital requirements debt service obligations industry practice legal requirements regulatory constraints factors board deems relevant information see item market registrant 's common equity related stockholder matters issuer purchases equity securities abbvie 's ability pay dividends depend ongoing ability generate cash operations access capital markets abbvie guarantee continue pay dividend future abbvie stockholder 's percentage ownership abbvie may diluted future future stockholder 's percentage ownership abbvie may diluted equity issuances capital market transactions equity awards abbvie granting abbvie 's directors officers employees acquisitions including abbvie 's pending acquisition allergan purposes abbvie 's employees options purchase shares common stock result conversion abbott stock options whole part abbvie stock options abbvie anticipates compensation committee grant additional stock options stockbased awards employees awards dilutive effect abbvie 's earnings per share could adversely affect market price abbvie 's common stock time time abbvie issue additional options stockbased awards employees abbvie 's employee benefits plans addition abbvie 's amended restated certificate incorporation authorizes abbvie issue without approval abbvie 's stockholders one classes series preferred stock designation powers preferences relative participating optional special rights including preferences abbvie 's common stock respecting dividends distributions abbvie 's board directors generally may determine terms one classes series preferred stock could dilute voting power reduce value abbvie 's common stock example abbvie could grant holders preferred stock right elect number abbvie 's directors events happening specified events right veto specified transactions similarly repurchase redemption rights liquidation preferences abbvie could assign holders preferred stock could affect residual value common stock certain provisions abbvie 's amended restated certificate incorporation amended restated bylaws delaware law may prevent delay acquisition abbvie could decrease trading price abbvie 's common stock abbvie 's amended restated certificate incorporation amended restated bylaws contain delaware law contains provisions intended deter coercive takeover practices inadequate takeover bids encouraging prospective acquirors negotiate abbvie 's board directors rather attempt hostile takeover provisions include among others inability abbvie 's stockholders call special meeting division abbvie 's board directors three classes directors class serving staggered threeyear term provision stockholders may remove directors cause ability abbvie 's directors stockholders fill vacancies abbvie 's board directors requirement affirmative vote stockholders holding least abbvie 's voting stock required amend certain provisions abbvie 's amended restated certificate incorporation abbvie 's amended restated bylaws relating number term election abbvie 's directors filling board vacancies calling special meetings stockholders director officer indemnification provisions addition section delaware general corporation law provides subject limited exceptions persons acquire affiliated person acquires outstanding voting stock delaware corporation shall engage business combination corporation including merger consolidation acquisitions additional shares threeyear period following date person affiliates becomes holder corporation 's outstanding voting stock abbvie believes provisions protect stockholders coercive otherwise unfair takeover tactics requiring potential acquirors negotiate abbvie 's board directors providing abbvie 's board directors time assess acquisition proposal provisions intended make company immune takeovers however provisions apply even offer may considered beneficial stockholders could delay prevent acquisition abbvie 's board directors determines best interests abbvie abbvie 's stockholders provisions may also prevent discourage attempts remove replace incumbent directors cautionary statement regarding forwardlooking statements annual report contains certain forward looking statements regarding business strategies market potential future financial performance matters words believe expect anticipate project similar expressions among others generally identify forward looking statements speak date statements made matters discussed forward looking statements subject risks uncertainties factors could cause actual results differ materially projected anticipated implied forward looking statements particular information included item business item risk factors item management 's discussion analysis financial condition results operations contain forward looking statements forward looking statement expectation belief future results events expressed expectation belief based current plans expectations abbvie management expressed good faith believed reasonable basis assurance expectation belief result achieved accomplished factors could cause actual results events differ materially anticipated include matters described item risk factors item management 's discussion analysis financial condition results operations abbvie undertake obligation update forward looking statements included annual report reflect events circumstances date hereof unless abbvie required applicable securities law item b unresolved staff comments none item properties abbvie 's corporate offices located north waukegan road north chicago illinois abbvie 's manufacturing facilities following locations united states outside united states abbott park illinois campoverde di aprilia italy barceloneta puerto rico cork ireland north chicago illinois ludwigshafen germany worcester massachusetts singapore wyandotte michigan sligo ireland leased property addition abbvie manufacturing facilities worldwide abbvie believes facilities suitable provide adequate production capacity material encumbrances abbvie 's owned properties united states including puerto rico abbvie one distribution center abbvie also research development facilities united states located abbott park illinois north chicago illinois redwood city california south san francisco california sunnyvale california cambridge massachusetts worcester massachusetts outside united states abbvie 's principal research development facilities located ludwigshafen germany item legal proceedings information pertaining legal proceedings provided note legal proceedings contingencies consolidated financial statements included item financial statements supplementary data incorporated reference herein item mine safety disclosures applicable form kinformation executive officers following table lists abbvie 's executive officers first appointed abbvie corporate officer december except otherwise indicated name age position richard gonzalez chairman board chief executive officer michael e severino md vice chairman president laura j schumacher vice chairman external affairs chief legal officer carlos alban vice chairman chief commercial officer henry gosebruch executive vice president chief strategy officer robert michael executive vice president chief financial officer timothy j richmond executive vice president chief human resources officer azita salekigerhardt phd executive vice president operations nicholas donoghoe md senior vice president enterprise innovation thomas j hudson md senior vice president research development chief scientific officer jeffrey r stewart senior vice president us commercial operations brian l durkin vice president controller dr severino first appointed corporate officer june mr gosebruch first appointed corporate officer december dr donoghoe first appointed corporate officer january mr michael first appointed corporate officer december dr hudson first appointed corporate officer july mr stewart first appointed corporate officer december mr durkin first appointed corporate officer october mr gonzalez chairman chief executive officer abbvie served abbotts executive vice president pharmaceutical products group july december responsible abbotts worldwide pharmaceutical business including commercial operations research development manufacturing also served president abbott ventures inc abbotts medical technology investment arm mr gonzalez joined abbott held various management positions dr severino abbvies vice chairman president responsible research development human resources operations corporate strategy office served executive vice president research development chief scientific officer dr severino served amgen inc senior vice president global development corporate chief medical officer vice president global development vice president therapeutic area head general medicine inflammation global clinical development joined abbvie ms schumacher abbvies vice chairman external affairs chief legal officer responsible global legal health economics outcomes research corporate responsibility brand communications government affairs prior current appointment served abbvies executive vice president external affairs general counsel corporate secretary prior abbvies separation abbott ms schumacher served executive vice president general counsel abbott abbvie ms schumacher also led business development ventures early stage collaborations ms schumacher joined abbott serves board general dynamics corporation mr alban abbvies vice chairman chief commercial officer responsible global commercial operations company including pharmacyclics commercial functions previously served executive vice president commercial operations served abbotts senior vice president proprietary pharmaceutical products global commercial operations senior vice president international pharmaceuticals vice president western europe canada vice president european operations mr alban joined abbott mr gosebruch abbvie 's executive vice president chief strategy officer worked years mergers acquisitions group jp morgan securities llc serving managing director since cohead north america mr gosebruch joined abbvie serves board aptinyx inc mr michael abbvies executive vice president chief financial officer mr michael previously served senior vice president chief financial officer october july vice president controller march october served abbvies vice president treasurer vice president controller commercial operations vice president financial planning analysis abbott mr michael served division controller nutrition supply chain mr michael joined abbott mr richmond abbvies executive vice president chief human resources officer served senior vice president human resources mr richmond served abbotts divisional vice president compensation benefits group vice president talent rewards divisional vice president talent acquisition mr richmond joined abbott dr salekigerhardt abbvies executive vice president operations served senior vice president operations dr saleki gerhardt served abbotts vice president pharmaceuticals manufacturing supply divisional vice president quality assurance global pharmaceutical operations dr salekigerhardt joined abbott serves board entegris inc dr donoghoe abbvie 's senior vice president enterprise innovation previously served partner mckinsey company leading firm 's west coast pharma biotechnology practice dr donoghoe joined firm supported multiple successful launches therapeutic areas oncology immunology primary care joined abbvie dr hudson abbvie 's senior vice president research development chief scientific officer previously served vice president head oncology discovery early development prior joining abbvie dr hudson served ontario institute cancer research president scientific director also previously served founder director mcgill university genome quebec innovation centre assistant director whiteheadmit center genome research mr stewart abbvies senior vice president us commercial operations mr stewart previously served abbvies president commercial operations prior abbvies separation abbott served vice president abbott proprietary pharmaceutical division united states mr stewart joined abbott mr durkin abbvies vice president controller mr durkin previously served vice president internal audit prior joining abbvie served vice president finance division controller abbotts vision care business controller pharmaceutical research development mr durkin joined abbott executive officers abbvie elected annually board directors officers elected board appointed chairman board officers either elected first meeting board directors held annual stockholder meeting appointed chairman board board meeting officer holds office successor duly elected appointed qualified officer 's death resignation removal family relationships executive officers listed form kpart ii item market registrant 's common equity related stockholder matters issuer purchases equity securities principal market principal market abbvie 's common stock new york stock exchange symbol abbv abbvie 's common stock also listed chicago stock exchange traded various regional electronic exchanges stockholders stockholders record abbvie common stock january performance graph following graph compares cumulative total returns abbvie sp index nyse arca pharmaceuticals index period december december graph assumes invested abbvie common stock index december also assumes reinvestment dividends stock price performance following graph necessarily indicative future stock price performance performance graph furnished shall deemed filed sec subject section securities exchange act shall deemed incorporated reference abbvie 's filings securities act amended dividends november abbvie 's board directors declared increase quarterly cash dividend per share per share payable february stockholders record january timing declaration amount payment dividends abbvie future within discretion board directors depend upon many factors including abbvie 's financial condition earnings capital requirements operating subsidiaries covenants associated certain abbvie 's debt service obligations legal requirements regulatory constraints industry practice ability access capital markets factors deemed relevant board directors moreover abbvie determines pay dividend future assurance continue pay dividends amount dividends issuer purchases equity securities c total number shares units total purchased part maximum number number b average publicly approximate dollar value shares price announced shares units may units paid per share plans yet purchased period purchased unit programs plans programs october october november november december december total addition abbvie shares repurchased open market publicly announced program shares also included shares purchased open market benefit participants abbvie employee stock purchase plan october november december shares include shares surrendered abbvie satisfy minimum tax withholding obligations connection vesting exercise stockbased awards form kitem selected financial data selected financial information read conjunction financial statements accompanying notes included item financial statements supplementary data item management 's discussion analysis financial condition results operations years ended december millions except per share data statement earnings data net revenues net earnings basic earnings per share diluted earnings per share cash dividends declared per common share weightedaverage basic shares outstanding weightedaverage diluted shares outstanding balance sheet data total assets longterm debt finance lease obligations ab november abbvie issued billion aggregate principal amount floating rate fixed rate unsecured senior notes maturities ranging months years abbvie expects use net proceeds fund portion aggregate cash consideration due allergan shareholders connection proposed acquisition pay related fees expenses see note consolidated financial statements information regarding proposed acquisition note information senior notes b includes current portion longterm debt finance lease obligations item management 's discussion analysis financial condition results operations following discussion analysis financial condition abbvie inc abbvie company december results operations three years period ended december commentary read conjunction consolidated financial statements accompanying notes appearing item financial statements supplementary data executive overview company overview abbvie global researchbased biopharmaceutical company formed following separation abbott laboratories abbott abbvie uses expertise dedicated people unique approach innovation develop market advanced therapies address world 's complex serious diseases abbvie 's products focused treating conditions chronic autoimmune diseases rheumatology gastroenterology dermatology oncology including blood cancers virology including hepatitis c virus hcv human immunodeficiency virus hiv neurological disorders parkinson 's disease metabolic diseases including thyroid disease complications associated cystic fibrosis pain associated endometriosis well serious health conditions abbvie also pipeline promising new medicines clinical development across important medical specialties immunology oncology neuroscience additional targeted investment cystic fibrosis women 's health abbvie 's products generally sold worldwide directly wholesalers distributors government agencies health care facilities specialty pharmacies independent retailers abbvieowned distribution centers public warehouses united states abbvie distributes pharmaceutical products principally independent wholesale distributors sales directly pharmacies patients outside united states abbvie sells products primarily customers distributors depending market served certain products comarketed copromoted companies abbvie approximately employees abbvie operates one business segmentpharmaceutical products june abbvie announced entered definitive transaction agreement abbvie acquire allergan plc allergan see note consolidated financial statements additional information regarding proposed acquisition financial results abbvie 's strategy focused delivering strong financial results advancing investing pipeline returning value shareholders ensuring strong sustainable growth business long term company 's financial performance included delivering worldwide net revenues billion operating earnings billion diluted earnings per share cash flows operations billion worldwide net revenues grew constant currency basis primarily driven revenue growth related imbruvica venclexta well continued strength humira us newly launched immunology assets skyrizi rinvoq offset international humira biosimilar competition diluted earnings per share included following aftertax costs billion change fair value contingent consideration liabilities ii billion related amortization intangible assets iii stemcentrxrelated impairment charge million net related fair value adjustment contingent consideration liabilities iv million acquired inprocess research development iprd v million expenses related proposed allergan acquisition costs partially offset following aftertax benefits million litigation matters primarily due settlement intellectual property dispute third party ii million due favorable resolution various tax positions iii million amended restated license agreement abbvie reata pharmaceuticals inc reata additionally financial results reflected continued funding support stages abbvies emerging pipeline assets continued investment abbvies market brands november abbvie 's board directors declared quarterly cash dividend per share common stock payable february reflects increase approximately previous quarterly dividend per share common stock form k strategic objectives abbvie 's mission innovationdriven patientfocused specialty biopharmaceutical company capable achieving toptier financial performance outstanding execution consistent stream innovative new medicines abbvie intends continue advance mission number ways including growing revenues diversifying revenue streams ensuring strong commercial execution new product launches driving latestage pipeline assets market ii continuing invest expand pipeline support opportunities immunology oncology neuroscience additional targeted investment cystic fibrosis women 's health well continued investment key onmarket products iii expanding operating margins iv returning cash shareholders via strong growing dividend also reducing incremental debt addition abbvie anticipates several regulatory submissions key data readouts key clinical trials next months abbvie expects achieve strategic objectives completion successful integration proposed allergan acquisition hematologic oncology revenue growth imbruvica venclexta immunology revenue growth driven successful commercial launches skyrizi rinvoq well humira us sales growth effective management humira international biosimilar erosion favorable impact pipeline products indications recently approved currently regulatory review approval expected products described greater detail section labeled research development included part item abbvie remains committed driving continued expansion operating margins expects achieve objective continued leverage revenue growth productivity initiatives supply chain ongoing efficiency programs optimize manufacturing commercial infrastructure administrative costs general corporate expenses combination abbvie allergan create diverse entity leadership positions across immunology hematologic oncology aesthetics neuroscience women 's health eye care virology abbvie 's existing product portfolio pipeline enhanced numerous allergan assets allergan 's product portfolio benefit abbvie 's commercial strength expertise international infrastructure research development research innovation cornerstones abbvie 's business global biopharmaceutical company abbvie 's longterm success depends great extent ability continue discover develop innovative pharmaceutical products acquire collaborate compounds currently development biotechnology pharmaceutical companies abbvie 's pipeline currently includes approximately compounds indications clinical development individually collaboration license agreements focused important medical specialties immunology oncology neuroscience along targeted investments cystic fibrosis women 's health programs approximately mid latestage development following sections summarize transitions significant programs phase development phase development well developments significant phase registration programs abbvie expects multiple phase programs transition phase programs next months significant programs developments immunology rinvoq february us food drug administration fda accepted priority review abbvie 's new drug application nda upadacitinib investigational oral jakselective inhibitor treatment adult patients moderate severe rheumatoid arthritis ra february abbvie initiated phase clinical trial evaluate efficacy safety upadacitinib subjects giant cell arteritis august fda approved rinvoq upadacitinib treatment adults moderately severely active ra inadequate response intolerance methotrexate october abbvie announced topline results first phase clinical trial rinvoq adult patients active psoriatic arthritis psa results selectpsa study evaluated rinvoq versus placebo patients adequately respond treatment one biologic dmards showed doses rinvoq mg mg met primary key secondary endpoints week safety profile consistent previous studies across indications new safety risks detected november abbvie announced data phase selectaxis trial twice many adult patients ankylosing spondylitis treated rinvoq achieved primary endpoint week versus placebo safety profile consistent previous studies across indications new safety risks detected november abbvie initiated phase clinical trial evaluate efficacy safety rinvoq adult patients axial spondyloarthritis december european commission ec granted marketing authorization rinvoq treatment adult patients moderate severe active rheumatoid arthritis inadequate response intolerance one dmards february abbvie announced topline results second phase clinical trial rinvoq adult patients active psa results selectpsa study evaluated rinvoq versus placebo patients adequately respond treatment one nonbiologic dmards showed doses rinvoq mg mg met primary key secondary endpoints safety profile consistent previous studies across indications new safety risks detected skyrizi march abbvie initiated two phase clinical trials evaluate efficacy safety risankizumab investigational interleukin il inhibitor subjects psoriatic arthritis april fda approved skyrizi risankizumab treatment moderate severe plaque psoriasis adults candidates systemic therapy phototherapy april ec granted marketing authorization skyrizi treatment moderate severe plaque psoriasis adult patients candidates systemic therapy oncology imbruvica january fda approved imbruvica combination gazyva obinutuzumab adult patients previously untreated chronic lymphocytic leukemia cllsmall lymphocytic lymphoma sll june abbvie announced results phase cll trial evaluating imbruvica patients previously untreated cll demonstrated imbruvica significantly improved event progressionfree survival november abbvie submitted supplemental new drug application snda fda imbruvica combination rituximab firstline treatment younger patients cll sll venclexta march abbvie announced fda placed partial clinical hold clinical trials evaluating venclexta investigational treatment multiple myeloma mm partial clinical hold followed review data ongoing phase bellini trial study relapsedrefractory mm higher proportion deaths observed venclexta arm compared control arm trial june abbvie announced fda lifted partial clinical hold placed phase canova trial evaluating venclexta investigational treatment relapsedrefractory mm positive translocation abnormality based upon agreement revisions canova study protocol including new risk mitigation measures protocolspecified guidelines updated futility criteria action impact approved indications venclexta cll acute myeloid leukemia aml may fda approved venclexta combination obinutuzumab adult patients previously untreated cllsll approval based data phase cll trial evaluating efficacy safety venclexta plus obinutuzumab versus obinutuzumab plus chlorambucil previously untreated patients cll demonstrated venclexta plus obinutuzumab prolonged progressionfree survival achieved higher rates complete response minimal residual diseasenegativity compared commonly used standard care obinutuzumab plus chlorambucil january abbvie announced committee medicinal products human use chmp european medicines agency ema granted positive opinion venclyxto combination obinutuzumab patients previously untreated cll depatuxm may abbvie announced decision discontinue phase intellance study depatuxizumab mafodotin depatuxm previously known abt patients newly diagnosed glioblastoma whose tumors egfr epidermal growth factor receptor amplification interim analysis independent data monitoring committee recommended stopping enrollment intellance due lack survival benefit patients receiving depatuxm compared placebo added standard regimen radiation temozolomide enrollment halted ongoing depatuxm studies veliparib july abbvie announced topline results phase brocade study evaluating veliparib investigational oral poly adenosine diphosphateribose polymerase parp inhibitor combination carboplatin paclitaxel met primary endpoint progressionfree survival patients negative germline brcamutated advanced breast cancer july abbvie announced topline results phase velia study conducted collaboration gog foundation inc evaluating veliparib carboplatin paclitaxel followed veliparib maintenance therapy met primary endpoint progressionfree survival patients newly diagnosed ovarian cancer regardless biomarker status rovat august abbvie announced decision terminate meru trial phase study evaluating rovalpituzumab tesirine rovat first line maintenance therapy advanced smallcell lung cancer sclc independent data monitoring committee recommended terminating study results demonstrated survival benefit preplanned interim analysis patients receiving rovat compared placebo closing meru trial abbvie announced termination rovat research development program virologyliver disease august ec granted marketing authorization maviret glecaprevirpibrentasvir shorten oncedaily treatment duration weeks treatmentnave compensated cirrhotic chronic hcv patients genotype gt infection september fda approved mavyret glecaprevirpibrentasvir shorten oncedaily treatment duration weeks treatmentnave compensated cirrhotic chronic hcv patients across genotypes gt january abbvie announced chmp ema recommended change marketing authorization maviret shorten oncedaily treatment duration weeks treatmentnave compensated cirrhotic chronic hcv patients gt infection neuroscience may abbvie initiated phase clinical trial evaluate safety tolerability abbv subcutaneous levodopacarbidopa delivery system subjects parkinson 's disease july abbvie announced decision discontinue phase arise study evaluating abbve investigational antitau antibody patients progressive supranuclear palsy independent data monitoring committee recommended stopping trial futility trial showed abbve provide efficacy july abbvie submitted nda fda elagolix combination estradiolnorethindrone acetate eneta daily addback therapy management heavy menstrual bleeding associated uterine fibroids results operations net revenues comparisons presented constant currency rates reflect comparative local currency net revenues prior year 's foreign exchange rates measure provides information change net revenues assuming foreign currency exchange rates changed prior current periods abbvie believes nongaap measure change net revenues constant currency rates used conjunction gaap measure change net revenues actual currency rates may provide complete understanding company 's operations facilitate analysis company 's results operations particularly evaluating performance one period another percent change actual currency rates constant currency rates years ended dollars millions united states international net revenues form kthe following table details abbvie 's worldwide net revenues percent change actual currency rates constant currency rates years ended december dollars millions immunology humira united states international total skyrizi united states nm nm nm nm international nm nm nm nm total nm nm nm nm rinvoq united states nm nm nm nm international nm nm nm nm total nm nm nm nm hematologic oncology imbruvica united states collaboration revenues total venclexta united states international total hcv mavyret united states international total viekira united states international total key products creon united states lupron united states international total synthroid united states synagis international duodopa united states international total sevoflurane united states international total kaletra united states international total androgel united states orilissa united states nm nm international nm nm nm nm total nm nm total net revenues nm meaningful following discussion analysis abbvie 's net revenues product presented constant currency basis global humira sales decreased increased sales decrease primarily driven direct biosimilar competition certain international markets partially offset market growth across therapeutic categories sales increase primarily driven market growth across therapeutic categories geographies well favorable pricing certain geographies united states humira sales increased sales increases primarily driven market growth across indications favorable pricing internationally humira revenues decreased increased sales decrease primarily driven direct biosimilar competition europe following expiration european union composition matter patent adalimumab october sales increase primarily driven market growth across indications partially offset direct biosimilar competition biosimilar competition humira expected united states abbvie continues pursue strategies intended differentiate humira competing products add sustainability humira net revenues skyrizi million following april regulatory approvals treatment moderate severe plaque psoriasis net revenues rinvoq million following august fda approval treatment moderate severe rheumatoid arthritis net revenues imbruvica represent product revenues united states collaboration revenues outside united states related abbvie 's share imbruvica profit abbvie 's global imbruvica revenues increased result continued penetration imbruvica patients cll well favorable pricing net revenues venclexta increased primarily due market share gains following additional regulatory approvals venclexta treatment patients relapsedrefractory cll firstline aml firstline cll global mavyret sales decreased primarily driven lower patient volumes certain international markets competitive dynamics us global mavyret sales increased result market share gains following fda ema approvals mavyret second half well geographic expansion global viekira sales decreased primarily due lower market share following launch mavyret net revenues creon increased primarily driven continued market growth favorable pricing creon maintains market leadership pancreatic enzyme market net revenues duodopa increased primarily driven increased market penetration gross margin percent change years ended december dollars millions gross margin percent net revenues gross margin percentage net revenues increased primarily due full year effect expiration humira royalties partially offset imbruvica profit sharing arrangement unfavorable impact higher intangible asset amortization gross margin percentage net revenues increased primarily due expiration humira royalties intangible asset impairment charge million partially offset imbruvica profit sharing arrangement form kselling general administrative percent change years ended december dollars millions selling general administrative percent net revenues selling general administrative sga expenses percentage net revenues decreased primarily due favorable impacts international humira expense reductions lower litigation reserve charges decreased million favorability partially offset new product launch expenses higher restructuring charges million transaction expenses associated proposed allergan transaction additionally sga expenses included nonrecurring philanthropic contributions million certain us notforprofit organizations sga expenses percentage net revenues increased primarily due new product launch expenses nonrecurring philanthropic contributions certain us notforprofit organizations partially offset continued leverage revenue growth research development acquired inprocess research development percent change years ended december dollars millions research development percent net revenues acquired inprocess research development research development rd expenses decreased increased principally due impairment charges related iprd acquired part stemcentrx acquisition company recorded billion intangible asset impairment charge represented remaining value iprd acquired following decision terminate rovat rd program company recorded billion intangible asset impairment charge following decision stop enrollment tahoe trial lowered probabilities success achieving regulatory approval across rovat earlystage assets obtained acquisition see note consolidated financial statements additional information regarding impairment charges acquired iprd expenses reflect upfront payments related various collaborations individually significant transactions cash flows acquired iprd expense included charge million result entering global strategic collaboration alector inc alector develop commercialize medicines treat alzheimers disease neurodegenerative disorders see note consolidated financial statements additional information regarding alector agreement operating expenses income operating income included million income legal settlement related intellectual property dispute third party million income related amended restated license agreement abbvie reata see note consolidated financial statements additional information reata agreement operating expenses included million charge related extension previously announced calico collaboration discover develop bring market new therapies patients agerelated diseases including neurodegeneration cancer see note consolidated financial statements additional information regarding calico agreement nonoperating expenses years ended december millions interest expense interest income interest expense net net foreign exchange loss expense net interest expense increased compared primarily due million incremental interest debt issuance costs associated financing proposed acquisition allergan well unfavorable impact higher interest rates company 's debt obligations interest expense increased compared primarily due unfavorable impact higher interest rates company 's debt obligations higher average outstanding debt balance interest income increased compared primarily due higher average cash cash equivalents balance partially offset decreased investments debt securities interest income increased compared primarily due higher interest rates net foreign exchange loss included million historical currency translation losses reclassified accumulated comprehensive income aoci related liquidation certain foreign entities following enactment us tax reform expense net included charges related change fair value contingent consideration liabilities billion million million fair value contingent consideration liabilities impacted passage time multiple inputs including probability success achieving regulatorycommercial milestones discount rates estimated amount future sales acquired products still development marketbased factors boehringer ingelheim bi contingent consideration liability increased due higher probabilities success higher estimated future sales declining interest rates passage time higher probabilities success primarily resulted april regulatory approvals skyrizi treatment moderate severe plaque psoriasis changes partially offset million decrease stemcentrx contingent consideration liability due termination rovat rd program third quarter bi contingent consideration liability increased due passage time higher estimated future sales partially offset effect rising interest rates increase bi contingent consideration liability primarily offset million decrease stemcentrx contingent consideration liability recorded fourth quarter due reduction probabilities success achieving regulatory approval across rovat earlystage stemcentrx assets change fair value represented mainly higher probabilities success passage time declining interest rates expense net also included realized gains availableforsale investment securities million income tax expense effective income tax rate negative effective tax rate period differed statutory tax rate principally due allocation company 's taxable earnings among jurisdictions benefit foreign operations reflects impact lower income tax rates locations outside united states tax incentives puerto rico foreign tax jurisdictions business development activities increase effective tax rate prior year principally due timing provisions tax cuts jobs act act related earnings certain foreign subsidiaries increase also attributable changes jurisdictional mix earnings including change fair value contingent consideration liabilities increases partially offset favorable resolution various tax positions current year effective tax rate also included effects stemcentrx intangible impairment related expenses effective tax rate included tax expense billion onetime mandatory repatriation previously untaxed earnings foreign subsidiaries partially offset billion net tax benefit remeasurement deferred taxes related act foreign tax law changes form kthe act significantly changed us corporate tax system act reduced us federal corporate tax rate created territorial tax system included new taxes certain foreign sourced earnings see note consolidated financial statements additional information regarding act financial position liquidity capital resources years ended december millions cash flows operating activities investing activities financing activities operating cash flows decreased slightly primarily due higher payments income taxes offset improved results operations resulting increase operating earnings operating cash flows increased primarily due improved results operations revenue growth decrease income tax payments operating cash flows also reflected abbvies contributions defined benefit plans million million million investing cash flows included net sales maturities investments totaling billion resulting sale substantially company 's investments debt securities payments made acquisitions investments billion capital expenditures million investing cash flows included payments made acquisitions investments million capital expenditures million partially offset net sales maturities investment securities totaling million investing cash flows included capital expenditures million payments made acquisitions investments million partially offset net sales maturities investment securities totaling million financing cash flows included issuance billion aggregate principal amount floating rate fixed rate unsecured senior notes maturities ranging months years abbvie expects use net proceeds billion fund portion aggregate cash consideration due allergan shareholders connection proposed acquisition pay related fees expenses pending consummation proposed allergan acquisition net proceeds offering permitted invested temporarily shortterm investments notes subject special mandatory redemption redemption price equal aggregate principal amount notes plus accrued unpaid interest proposed acquisition allergan completed january company notifies trustee respect notes pursue consummation proposed allergan acquisition additionally financing cash flows included issuance billion aggregate principal amount unsecured senior euro notes company used redeem billion aggregate principal amount senior euro notes due mature november well repayment billion day term loan credit agreement scheduled mature june financing cash flows included proceeds issuance billion drawn term loan june september company issued billion aggregate principal amount unsecured senior notes billion net proceeds billion used repay company 's outstanding threeyear term loan credit agreement september billion used repay aggregate principal amount senior notes maturity november financing cash flows also included may repayment billion aggregate principal amount company 's senior notes maturity company issued redeemed commercial paper commercial paper borrowings outstanding december million outstanding december abbvie may issue additional commercial paper retire commercial paper meet liquidity requirements needed cash dividend payments totaled billion billion billion increase cash dividend payments primarily driven increase dividend rate november abbvie announced board directors declared increase quarterly cash dividend per share per share beginning dividend payable february stockholders record january reflects increase approximately previous quarterly rate timing declaration amount payment dividends abbvie future within discretion board directors depend upon many factors including abbvie 's financial condition earnings capital requirements operating subsidiaries covenants associated certain abbvie 's debt service obligations legal requirements regulatory constraints industry practice ability access capital markets factors deemed relevant board directors february abbvie 's board directors authorized new billion stock repurchase program superseded abbvie 's previous stock repurchase program december abbvie 's board directors authorized billion increase existing billion stock repurchase program company 's stock repurchase authorization permits purchases abbvie shares time time openmarket private transactions managements discretion program time limit discontinued time authorization abbvie repurchased million shares million million shares billion abbvie cashsettled million december open market purchases january abbvie 's remaining stock repurchase authorization billion december previous stock repurchase programs abbvie made open market share repurchases million shares billion million shares billion abbvie cashsettled million december open market purchases january abbvie made contingent consideration milestone royalty payments bi totaling million following commercial launch skyrizi certain geographies million payments included financing cash flows million payments included operating cash flows abbvie paid million contingent consideration bi related bla maa acceptance milestones million payments included financing cash flows million payments included operating cash flows abbvie paid million contingent consideration bi related phase enrollment milestone million milestone included financing cash flows million included operating cash flows connection proposed acquisition allergan june abbvie entered billion day bridge credit agreement july abbvie entered billion term loan credit agreement company incurred total million debt issuance costs related two agreements october abbvie commenced offers exchange outstanding notes certain series issued allergan billion aggregate principal amount billion aggregate principal amount new notes issued abbvie cash subject conditions including closing proposed acquisition see note consolidated financial statements additional information february remaining commitments bridge credit agreement reduced result cash hand abbvie abbvie subsequently terminated bridge credit agreement entirety permitted terms credit risk abbvie monitors economic conditions creditworthiness customers government regulations funding domestically abroad abbvie regularly communicates customers regarding status receivable balances including payment plans obtains positive confirmation validity receivables abbvie establishes allowance accounts receivable probable collected abbvie may also utilize factoring arrangements mitigate credit risk although receivables included arrangements historically significant amount total outstanding receivables credit facility access capital credit ratings credit facility august abbvie entered amended restated billion fiveyear revolving credit facility matures august amended facility enables company borrow funds unsecured basis variable interest rates contains various covenants december company compliance credit facility covenants commitment fees credit facility insignificant amounts outstanding company 's credit facilities december access capital company intends fund shortterm longterm financial obligations mature cash hand future cash flows operations issuing additional debt company 's ability generate cash flows operations issue debt enter financing arrangements acceptable terms could adversely affected material decline demand company 's products solvency customers suppliers deterioration company 's key financial ratios credit ratings material unfavorable changes business conditions current time company believes sufficient financial flexibility issue debt enter financing arrangements attract longterm capital acceptable terms support company 's growth objectives form kcredit ratings following announcement proposed acquisition allergan billion senior notes issuance moody 's investor service affirmed baa senior unsecured longterm rating prime shortterm rating stable outlook sp global ratings revised ratings outlook negative stable expects lower issuer credit rating one notch bbb shortterm rating acquisition complete unfavorable changes ratings may adverse impact future financing arrangements however would affect company 's ability draw credit facility would result acceleration scheduled maturities company 's outstanding debt contractual obligations following table summarizes abbvie 's estimated contractual obligations december less one three millions total one year three years five years five years longterm debt including current portion interest longterm debta noncancelable operating finance lease paymentsf purchase obligations otherb longterm liabilities c e total includes estimated future interest payments longterm debt interest payments debt calculated future periods using forecasted interest rates effect end projected interest payments include related effects interest rate swap agreements certain projected interest payments may differ future based changes floating interest rates factors events projected interest payments pertain obligations agreements outstanding december see note consolidated financial statements additional information regarding company 's debt instruments note additional information interest rate swap agreements outstanding december b includes company 's significant unconditional purchase obligations commitments exceed company 's projected requirements made normal course business c excludes liabilities associated company 's unrecognized tax benefits possible reliably estimate timing future cash outflows related liabilities see note consolidated financial statements additional information unrecognized tax benefits includes billion contingent consideration liabilities recorded fair value consolidated balance sheet potential contingent consideration payments exceed fair value recorded consolidated balance sheet included table contractual obligations see note consolidated financial statements additional information regarding liabilities e includes onetime transition tax liability mandatory deemed repatriation previously untaxed earnings foreign subsidiaries resulting us tax reform enacted onetime transition tax generally payable eight annual installments see note consolidated financial statements additional information regarding tax liabilities f lease payments include approximately million contractual minimum lease payments leases executed yet commenced leases commence lease terms approximately years abbvie enters rd collaboration arrangements third parties may require future milestone payments third parties contingent upon achievement certain development regulatory commercial milestones individually arrangements insignificant one annual reporting period however milestones multiple products covered arrangements would happen reached reporting period aggregate charge expense could material results operations period business perspective payments viewed positive signify product successfully moving development generating likely generate future cash flows product sales possible predict reasonable certainty whether milestones achieved timing achievement result potential payments included table contractual obligations see note consolidated financial statements additional information collaboration arrangements critical accounting policies estimates preparation financial statements accordance generally accepted accounting principles united states requires use estimates assumptions affect reported amounts assets liabilities reported amounts revenue expenses summary company 's significant accounting policies included note consolidated financial statements certain policies considered critical significantly impact company 's financial condition results operations require difficult subjective complex judgments often result need make estimates effect matters inherently uncertain actual results may vary estimates revenue recognition abbvie recognizes revenue control promised goods services transferred companys customers amount reflects consideration abbvie expects entitled exchange goods services sales value add taxes collected concurrent revenue producing activities excluded revenue abbvie generates revenue primarily product sales majority sales company transfers control invoices customer recognizes revenue upon shipment customer rebates abbvie provides rebates pharmacy benefit managers state government medicaid programs insurance companies administer medicare drug plans wholesalers group purchasing organizations government agencies private entities rebate chargeback accruals accounted variable consideration recorded reduction revenue period related product sold rebates chargebacks totaled billion billion billion rebate amounts typically based upon volume purchases using contractual statutory prices may vary product payer type rebate factors used calculations accrual rebate include identification products subject rebate applicable price terms estimated lag time sale payment rebate significant order establish rebate chargeback accruals company uses internal external data estimate level inventory distribution channel rebate claims processing lag time type rebate estimate rebate percentage net price company tracks sales product customer payer company evaluates inventory data reported wholesalers available prescription volume information product pricing historical experience factors order determine adequacy reserves abbvie regularly monitors reserves records adjustments rebate trends rebate programs contract terms legislative changes significant events indicate change reserve appropriate historically adjustments rebate accruals material net earnings form kthe following table analysis three largest rebate accruals chargeback allowances comprise approximately total consolidated rebate chargebacks recorded reductions revenues remaining rebate provisions charged gross revenues significant determination operating earnings medicaid managed medicare care wholesaler millions rebates rebates chargebacks balance december provisions payments balance december provisions payments balance december provisions payments balance december cash discounts product returns cash discounts product returns totaled billion billion billion accounted variable consideration recorded reduction revenue period related product sold reserve cash discounts readily determinable company 's experience payment history fairly consistent product returns reliably estimated based company 's historical return experience pension postemployment benefits abbvie engages outside actuaries assist determination obligations costs pension postemployment benefit plans direct obligations abbvie valuation funded status net periodic benefit cost plans calculated using actuarial assumptions significant assumptions reviewed annually include discount rate expected longterm rate return plan assets health care cost trend rates disclosed note consolidated financial statements discount rate selected based current market rates highquality fixedincome investments december year abbvie employs yield curve approach countries robust bond market exists yield curve developed using highquality bonds yieldcurve approach reflects plans ' specific cash flows ie duration calculating benefit obligations applying corresponding individual spot rates along yield curve abbvie reflects plans ' specific cash flows applies corresponding individual spot rates along yield curve calculating service cost interest cost portions expense countries abbvie reviews various indices corporate bond government bond benchmarks estimate discount rate abbvie 's assumed discount rates significant effect amounts reported defined benefit pension postemployment plans december basis point change assumed discount rate would following effects abbvie 's calculation net periodic benefit costs projected benefit obligations december basis point millions brackets denote reduction increase decrease defined benefit plans service interest cost projected benefit obligation postemployment plans service interest cost projected benefit obligation expected longterm rate return based asset allocation historical performance current view expected future returns abbvie considers inputs longterm focus avoid shortterm market influences current longterm rate return plan assets plan supported historical performance trust 's actual target asset allocation abbvie 's assumed expected longterm rate return significant effect amounts reported defined benefit pension plans december used calculation net periodic benefit cost one percentage point change assumed expected longterm rate return plan assets would increase decrease net period benefit cost plans million health care cost trend rate selected reviewing historical trends current views projected future health care cost increases current health care cost trend rate supported historical trend experience plan assumed health care cost trend rates significant effect amounts reported health care plans december used calculation net periodic benefit cost one percentage point change assumed health care cost trend rates would following effects abbvie 's calculation net periodic benefit costs projected benefit obligation december one percentage point millions brackets denote reduction increase decrease service interest cost projected benefit obligation income taxes abbvie accounts income taxes asset liability method provisions federal state foreign income taxes calculated reported pretax earnings based current tax laws deferred taxes provided using enacted tax rates future tax consequences temporary differences differences financial statement carrying amount assets liabilities respective tax bases tax benefits carryforwards valuation allowance established maintained based currently available information likely portion deferred tax asset realized litigation company subject contingencies various claims legal proceedings investigations regarding product liability intellectual property commercial securities matters arise normal course business see note consolidated financial statements additional information loss contingency provisions recorded probable losses management 's best estimate loss best estimate made minimum loss contingency amount within probable range recorded accordingly abbvie often initially unable develop best estimate loss therefore minimum amount could zero recorded information becomes known either minimum loss amount increased resulting additional loss provisions best estimate made also resulting additional loss provisions occasionally best estimate amount changed lower amount events result expectation favorable outcome previously expected valuation goodwill intangible assets abbvie acquired may continue acquire significant intangible assets connection business combinations abbvie records fair value transactions involving purchase sale intangible assets occur frequency companies pharmaceuticals industry valuations usually based discounted cash flow analysis incorporating stage completion discounted cash flow model requires assumptions timing amount future net cash flows risk cost capital terminal values market participants factors significantly affect value intangible asset iprd acquired business combination capitalized indefinitelived intangible asset regulatory approval obtained time accounted definitelived asset amortized estimated useful life discontinuation point intangible asset written iprd acquired transactions business combinations expensed immediately unless deemed alternative future use payments made third parties subsequent regulatory approval capitalized amortized remaining useful life abbvie reviews recoverability definitelived intangible assets whenever events changes circumstances indicate carrying value asset may recoverable goodwill indefinitelived intangible assets reviewed impairment annually event occurs could result impairment see note consolidated financial statements information annually company tests goodwill impairment first assessing qualitative factors determine whether likely fair value less carrying amount factors considered assessment include general macroeconomic conditions conditions specific industry market cost factors overall financial form kperformance whether sustained declines company 's share price company concludes likely fair value reporting unit less carrying amount quantitative impairment test performed abbvie tests indefinitelived intangible assets impairment first assessing qualitative factors determine whether likely fair value less carrying amount company concludes likely fair value less carrying amount quantitative impairment test performed quantitative impairment tests company uses estimated future cash flow approach requires significant judgment respect future volume revenue expense growth rates changes working capital use selection appropriate discount rate asset groupings assumptions estimates estimates assumptions used consistent company 's business plans market participant 's views use alternative estimates assumptions could increase decrease estimated fair value assets could potentially impact company 's results operations actual results may differ company 's estimates contingent consideration fair value measurements contingent consideration liabilities determined acquisition date based significant unobservable inputs including discount rate estimated probabilities timing achieving specified development regulatory commercial milestones estimated amount future sales acquired products contingent consideration liabilities revalued fair value subsequent reporting date related contingency resolved potential contingent consideration payments estimated applying probabilityweighted expected payment model contingent milestone payments monte carlo simulation model contingent royalty payments discounted present value changes fair value contingent consideration liabilities result changes one number inputs including discount rates probabilities achieving milestones time required achieve milestones estimated future sales significant judgment employed determining appropriateness certain inputs changes inputs described could material impact company 's financial position results operations given period december basis point increasedecrease assumed discount rate would decreasedincreased value contingent consideration liabilities approximately million additionally december five percentage point increasedecrease assumed probability success across potential indications would increaseddecreased value contingent consideration liabilities approximately million recent accounting pronouncements see note consolidated financial statements additional information recent accounting pronouncements item quantitative qualitative disclosures market risk company exposed risk earnings cash flows equity could adversely impacted changes foreign exchange rates interest rates certain derivative instruments used available costeffective basis hedge company 's underlying economic exposures see note consolidated financial statements additional information regarding company 's financial instruments hedging strategies foreign currency risk abbvie 's primary net foreign currency exposures euro japanese yen canadian dollar british pound following table reflects total foreign currency forward exchange contracts outstanding december weighted fair weighted fair average carrying average carrying contract exchange value contract exchange value millions amount rate receivablepayable amount rate receivablepayable receive primarily us dollars exchange following currencies euro japanese yen canadian dollar british pound currencies na na total company estimates appreciation underlying currencies hedged levels us dollar variables held constant would decrease fair value foreign exchange forward contracts million december realized appreciation would negatively affect earnings remaining life contracts however gains losses hedging instruments offset losses gains hedged transactions reduce earnings stockholders ' equity volatility relating foreign exchange appreciation believed reasonably possible nearterm change foreign currencies december company billion aggregate principal amount unsecured senior euro notes outstanding exposed foreign currency risk company designated foreign currency denominated notes hedges net investments certain foreign subsidiaries affiliates result foreign currency translation gains losses related euro notes included accumulated comprehensive income see note consolidated financial statements additional information regarding senior euro notes note consolidated financial statements additional information regarding net investment hedging program interest rate risk company estimates increase interest rates basis points would adversely impact fair value abbvie 's interest rate swap contracts approximately million december realized fair value reduction would affect earnings remaining life contracts company estimates increase basis points longterm interest rates would decrease fair value longterm debt billion december basis point change believed reasonably possible nearterm change interest rates form kitem financial statements supplementary data consolidated financial statements consolidated statements earnings consolidated statements comprehensive income consolidated balance sheets consolidated statements equity consolidated statements cash flows notes consolidated financial statements report independent registered public accounting firm abbvie inc subsidiaries consolidated statements earnings years ended december millions except per share data net revenues cost products sold selling general administrative research development acquired inprocess research development operating expense income total operating costs expenses operating earnings interest expense net net foreign exchange loss expense net earnings income tax income tax expense benefit net earnings per share data basic earnings per share diluted earnings per share weightedaverage basic shares outstanding weightedaverage diluted shares outstanding accompanying notes integral part consolidated financial statements form kabbvie inc subsidiaries consolidated statements comprehensive income years ended december millions net earnings foreign currency translation adjustments net tax expense benefit net investment hedging activities net tax expense benefit pension postemployment benefits net tax expense benefit marketable security activities net tax expense benefit cash flow hedging activities net tax expense benefit comprehensive income loss comprehensive income accompanying notes integral part consolidated financial statements abbvie inc subsidiaries consolidated balance sheets december millions except share data assets current assets cash equivalents shortterm investments accounts receivable net inventories prepaid expenses total current assets investments property equipment net intangible assets net goodwill assets total assets liabilities equity current liabilities shortterm borrowings current portion longterm debt finance lease obligations accounts payable accrued liabilities total current liabilities longterm debt finance lease obligations deferred income taxes longterm liabilities commitments contingencies stockholders equity deficit common stock par value shares authorized shares issued december december common stock held treasury cost shares december december additional paidin capital retained earnings accumulated comprehensive loss total stockholders equity deficit total liabilities equity accompanying notes integral part consolidated financial statements form kabbvie inc subsidiaries consolidated statements equity accumulated common additional shares common treasury paidin retained comprehensive years ended december millions outstanding stock stock capital earnings loss total balance december net earnings comprehensive loss net tax dividends declared purchases treasury stock stockbased compensation plans balance december adoption new accounting standardsa net earnings comprehensive income net tax dividends declared purchases treasury stock stockbased compensation plans balance december net earnings comprehensive loss net tax dividends declared purchases treasury stock stockbased compensation plans balance december adoption new accounting standards primarily includes cumulativeeffect adjustment accounting standards update asu income taxes topic intraentity transfers assets inventory accompanying notes integral part consolidated financial statements abbvie inc subsidiaries consolidated statements cash flows years ended december millions brackets denote cash outflows cash flows operating activities net earnings adjustments reconcile net earnings net cash operating activities depreciation amortization intangible assets change fair value contingent consideration liabilities stockbased compensation upfront costs milestones related collaborations gain divestitures intangible asset impairment impacts related us tax reform net changes operating assets liabilities accounts receivable inventories prepaid expenses assets accounts payable liabilities cash flows operating activities cash flows investing activities acquisitions investments acquisitions property equipment purchases investment securities sales maturities investment securities cash flows investing activities cash flows financing activities net change commercial paper borrowings proceeds issuance shortterm borrowings repayments shortterm borrowings proceeds issuance longterm debt repayments longterm debt finance lease obligations debt issuance costs dividends paid purchases treasury stock proceeds exercise stock options payments contingent consideration liabilities net cash flows financing activities effect exchange rate changes cash equivalents net change cash equivalents cash equivalents beginning year cash equivalents end year supplemental information interest paid net portion capitalized income taxes paid received accompanying notes integral part consolidated financial statements form kabbvie inc subsidiaries notes consolidated financial statements note background background principal business abbvie inc abbvie company discovery development manufacture sale broad line pharmaceutical products abbvie 's products generally sold worldwide directly wholesalers distributors government agencies health care facilities specialty pharmacies independent retailers abbvieowned distribution centers public warehouses united states abbvie distributes pharmaceutical products principally independent wholesale distributors sales directly pharmacies patients outside united states abbvie sells products primarily customers distributors depending market served abbvie incorporated delaware april january abbvie became independent publiclytraded company result distribution abbott laboratories abbott outstanding common stock abbvie abbott 's shareholders june abbvie announced entered definitive transaction agreement abbvie acquire allergan plc allergan see note additional information regarding proposed acquisition note summary significant accounting policies use estimates consolidated financial statements prepared accordance us generally accepted accounting principles gaap necessarily include amounts based estimates assumptions management actual results could differ amounts significant estimates include amounts rebates pension postemployment benefits income taxes litigation valuation goodwill intangible assets contingent consideration liabilities financial instruments inventory accounts receivable exposures basis consolidation consolidated financial statements include accounts abbvie subsidiaries controlling interest maintained controlling interest determined majority ownership interest absence substantive thirdparty participating rights case variable interest entities abbvie determined primary beneficiary investments companies abbvie significant influence controlling interest accounted using equity method abbvie 's share earnings losses reported expense net consolidated statements earnings intercompany balances transactions eliminated certain reclassifications made conform prior period consolidated financial statements current period presentation revenue recognition abbvie recognizes revenue control promised goods services transferred companys customers amount reflects consideration abbvie expects entitled exchange goods services sales value add taxes collected concurrent revenue producing activities excluded revenue abbvie generates revenue primarily product sales majority sales company transfers control invoices customer recognizes revenue upon shipment customer company recognizes shipping handling costs expense cost products sold company transfers control customer payment terms vary depending type location customer based customary commercial terms generally less one year abbvie adjust revenue effects significant financing component contracts abbvie expects period transfer good service collection one year less discounts rebates sales incentives customers returns certain adjustments accounted variable consideration provisions variable consideration based current pricing executed contracts government pricing legislation historical data provided period related revenues recorded rebate amounts typically based upon volume purchases using contractual statutory prices may vary product payer type rebate factors used calculation accrual include identification products subject rebate applicable price terms estimated lag time sale payment rebate significant sales incentives customers insignificant addition revenue contracts customers company also recognizes certain collaboration revenues see note additional information related collaboration janssen biotech inc additionally see note disaggregation revenue product geography research development expenses internal research development rd costs expensed incurred clinical trial costs incurred third parties expensed contracted work performed contingent milestone payments due third parties research development collaborations prior regulatory approval payment obligations expensed milestone results achieved payments made third parties subsequent regulatory approval capitalized intangible assets amortized cost products sold remaining useful life related product collaborations arrangements company enters collaborative agreements third parties develop commercialize drug candidates collaborative activities may include joint research development commercialization new products abbvie generally receives certain licensing rights arrangements collaborations often require upfront payments may include additional milestone research development cost sharing royalty profit share payments contingent upon occurrence certain future events linked success asset development commercialization upfront payments associated collaborative arrangements development stage expensed acquired inprocess research development iprd expenses consolidated statements earnings subsequent payments made partner achievement milestones development stage expensed rd expense consolidated statements earnings milestone achieved milestone payments made partner subsequent regulatory approval capitalized intangible assets amortized cost products sold estimated useful life related asset royalties expensed cost products sold consolidated statements earnings incurred advertising costs associated advertising expensed incurred included selling general administrative sga expense consolidated statements earnings advertising expenses billion billion million pension postemployment benefits abbvie records annual expenses relating defined benefit pension postemployment benefit plans based calculations utilize various actuarial assumptions including discount rates rates return assets compensation increases turnover rates health care cost trend rates abbvie reviews actuarial assumptions annual basis makes modifications assumptions based current rates trends actuarial gains losses deferred accumulated comprehensive income aoci net tax amortized remaining service attribution periods employees corridor method differences expected longterm return plan assets actual annual return amortized net periodic benefit cost fiveyear period income taxes income taxes accounted asset liability method provisions federal state foreign income taxes calculated reported pretax earnings based current tax laws deferred taxes provided using enacted tax rates future tax consequences temporary differences differences financial statement carrying amounts assets liabilities respective tax bases tax benefits carryforwards valuation allowance established maintained based currently available information likely portion deferred tax asset realized cash equivalents cash equivalents include money market funds time deposits original maturities three months less investments investments consist primarily time deposits marketable debt securities heldtomaturity debt securities equity securities investments marketable debt securities classified availableforsale recorded fair value form kunrealized holding gains losses net tax included aoci consolidated balance sheets realized time gains losses recognized earnings investments equity securities readily determinable fair values recorded fair value investments equity securities readily determinable fair values recorded cost remeasured fair value based certain observable price changes impairment events occur heldtomaturity debt securities recorded cost gains losses investments included expense net consolidated statements earnings abbvie periodically assesses marketable debt securities otherthantemporary impairment losses evaluation based number factors including length time extent fair value cost basis adverse conditions related specifically security including changes credit rating security intent sell whether abbvie likely required sell security recovery amortized cost basis abbvie also considers industry factors general market trends abbvie determines otherthantemporary decline occurred cost basis investment written charge expense net consolidated statements earnings availableforsale investment 's unrealized loss reclassified aoci expense net consolidated statements earnings realized gains losses sales investments computed using firstin firstout method adjusted otherthantemporary declines fair value recorded net earnings accounts receivable accounts receivable stated net realizable value allowance doubtful accounts reflects best estimate probable losses inherent receivables portfolio determined basis historical experience specific allowances known troubled accounts currently available information accounts receivable written reasonable means collect full amount including litigation appropriate exhausted allowance doubtful accounts million december million december inventories inventories valued lower cost firstin firstout basis market cost includes material conversion costs inventories consisted following december millions finished goods workinprocess raw materials inventories property equipment december millions land buildings equipment construction progress property equipment gross less accumulated depreciation property equipment net depreciation property equipment recorded straightline basis estimated useful lives assets estimated useful life buildings ranges years buildings include leasehold improvements amortized life related facility lease including renewal periods appropriate asset whichever shorter estimated useful life equipment ranges years equipment includes certain computer software software development costs incurred connection developing obtaining software internal use amortized years depreciation expense million million million leases shortterm leases term months less recorded balance sheet leases commencing modified later abbvie separate lease components nonlease components company records lease liabilities based present value lease payments lease term abbvie generally uses incremental borrowing rate discount lease liabilities rate implicit lease typically readily determinable certain lease agreements include renewal options company 's control abbvie includes optional renewal periods lease term reasonably certain abbvie exercise option variable lease payments include payments lessors taxes maintenance insurance operating costs well payments adjusted based index rate company 's lease agreements contain significant residual value guarantees restrictive covenants litigation contingencies loss contingency provisions recorded probable liability incurred amount liability reasonably estimated based existing information best estimate made minimum loss contingency amount probable range recorded legal fees expensed incurred abbvie accrues product liability claims undiscounted basis liabilities evaluated quarterly adjusted necessary additional information becomes available receivables insurance recoveries product liability claims recorded assets undiscounted basis probable recovery realized business combinations abbvie utilizes acquisition method accounting business combinations method requires among things results operations acquired companies included abbvie 's results operations beginning respective acquisition dates assets acquired liabilities assumed recognized fair value acquisition date excess fair value consideration transferred fair values net assets acquired recognized goodwill contingent consideration liabilities recognized estimated fair value acquisition date subsequent changes fair value contingent consideration liabilities recognized expense net consolidated statements earnings fair value assets acquired liabilities assumed certain cases may subject revision based final determination fair value period time exceed months acquisition date legal costs due diligence costs business valuation costs business acquisition costs expensed incurred goodwill intangible assets intangible assets acquired business combination recorded fair value using discounted cash flow model discounted cash flow model requires assumptions timing amount future net cash flows risk cost capital terminal values market participants definitelived intangibles amortized estimated useful lives using estimated pattern economic benefit abbvie reviews recoverability definitelived intangible assets whenever events changes circumstances indicate carrying value asset may recoverable abbvie first compares projected undiscounted cash flows generated asset carrying value undiscounted cash flows intangible asset less carrying value intangible asset written fair value cash flows identified individual asset review applied lowest level cash flows largely independent cash flows assets liabilities goodwill indefinitelived assets amortized subject impairment review annually frequently indicators impairment exist impairment goodwill could occur carrying amount reporting unit exceeded fair value reporting unit impairment indefinitelived intangible assets would occur fair value intangible asset less carrying value company tests goodwill impairment first assessing qualitative factors determine whether likely fair value less carrying amount company concludes likely fair value reporting unit less carrying amount quantitative impairment test performed abbvie tests indefinitelived intangible assets impairment first assessing qualitative factors determine whether likely fair value less carrying amount company concludes likely fair value less carrying amount quantitative impairment test performed quantitative impairment tests company uses estimated future cash flow approach requires significant judgment respect future volume revenue expense growth rates changes working capital use selection appropriate discount rate asset groupings assumptions estimates estimates assumptions used consistent company 's business plans market participant 's views use alternative estimates assumptions could increase decrease form kthe estimated fair value assets potentially result different impacts company 's results operations actual results may differ company 's estimates acquired inprocess research development asset acquisition initial costs rights iprd projects acquired expensed iprd consolidated statements earnings unless project alternative future use costs include initial payments incurred prior regulatory approval connection research development collaboration agreements provide rights develop manufacture market andor sell pharmaceutical products business combination fair value iprd projects acquired capitalized accounted indefinitelived intangible assets underlying project receives regulatory approval point intangible asset accounted definitelived intangible asset discontinuation point intangible asset written rd costs incurred acquisition expensed incurred foreign currency translation foreign subsidiary earnings translated us dollars using average exchange rates net assets foreign subsidiaries translated us dollars using periodend exchange rates us dollar effects arise translating net assets subsidiaries changing rates recognized comprehensive income loss oci consolidated statements comprehensive income net assets subsidiaries highly inflationary economies remeasured functional currency reporting currency remeasurement recognized net foreign exchange loss consolidated statements earnings derivatives derivative instruments recognized either assets liabilities fair value consolidated balance sheets classified current longterm based scheduled maturity instrument derivatives formally designated hedges company assesses inception quarterly thereafter whether hedging derivatives highly effective offsetting changes fair value cash flows hedged item changes fair value derivative designated fair value hedge hedged item attributable hedged risk recognized earnings immediately effective portions changes fair value derivative designated cash flow hedge reported aoci subsequently recognized earnings consistent underlying hedged item determined derivative longer highly effective hedge company discontinues hedge accounting prospectively hedged forecasted transaction becomes probable occurring gains losses reclassified aoci earnings derivatives designated hedges adjusted fair value current earnings company also uses derivative instruments foreign currency denominated debt hedge net investments certain foreign subsidiaries affiliates realized unrealized gains losses hedges included aoci derivative cash flows exception net investment hedges principally classified operating section consolidated statements cash flows consistent underlying hedged item cash flows related net investment hedges classified investing section consolidated statements cash flows recent accounting pronouncements recently adopted accounting pronouncements asu february financial accounting standards board fasb issued asu leases topic standard outlined comprehensive lease accounting model superseded previous lease guidance required lessees recognize lease liabilities corresponding rightofuse assets leases lease terms greater months guidance also changed definition lease expanded disclosure requirements lease arrangements abbvie adopted standard first quarter using modified retrospective method results reporting periods beginning december presented accordance standard results prior periods adjusted continue reported accordance abbvie 's historical accounting cumulative effect initially applying new leases standard recognized adjustment opening consolidated balance sheet january company elected package practical expedients leases commenced prior january reassess historical conclusions whether expired existing contracts contain leases ii lease classification expired existing leases iii initial direct costs capitalization existing leases new standard january company recognized cumulativeeffect adjustment consolidated balance sheet primarily related recognition liabilities corresponding rightofuse assets operating leases adjustment consolidated balance sheet included million increase assets ii million increase accounts payable accrued liabilities iii million increase longterm liabilities cumulativeeffect adjustments consolidated balance sheet insignificant adoption standard significant impact abbvie 's consolidated statement earnings asu february fasb issued asu income statement reporting comprehensive income topic reclassification certain tax effects accumulated comprehensive income allowed reclassification aoci retained earnings stranded tax effects related adjustments deferred taxes resulting december enactment tax cuts jobs act act abbvie adopted standard first quarter upon adoption company made election reclassify income tax effects act aoci retained earnings therefore adoption standard impact abbvie 's consolidated financial statements recent accounting pronouncements yet adopted asu june fasb issued asu financial instruments credit losses topic standard changes credit losses measured financial assets certain instruments trade receivables heldtomaturity debt securities loans financial instruments standard requires use new forwardlooking expected credit loss model generally result earlier recognition allowances losses availableforsale debt securities unrealized losses standard requires allowances recorded instead reducing amortized cost investment additionally standard requires new disclosures effective abbvie starting first quarter certain exceptions adjustments applied using modifiedretrospective approach reflecting adjustments cumulativeeffect impact retained earnings beginning fiscal year adoption abbvie completed assessment new standard december concluded adoption material impact consolidated financial statements based company 's current portfolio financial assets asu december fasb issued asu income taxes topic standard includes simplifications related accounting income taxes including removing certain exceptions related approach intraperiod tax allocation recognition deferred tax liabilities outside basis differences standard also clarifies accounting transactions result stepup tax basis goodwill standard effective abbvie starting first quarter early adoption permitted abbvie currently assessing impact timing adopting guidance consolidated financial statements form knote supplemental financial information interest expense net years ended december millions interest expense interest income interest expense net accounts payable accrued liabilities december millions sales rebates dividends payable accounts payable salaries wages commissions royalty license arrangements accounts payable accrued liabilities longterm liabilities december millions contingent consideration liabilities income taxes payable pension postemployment benefits liabilities unrecognized tax benefits longterm liabilities note earnings per share abbvie grants certain restricted stock units rsus considered participating securities due presence participating securities abbvie calculates earnings per share eps using dilutive treasury stock twoclass method periods presented twoclass method dilutive following table summarizes impact twoclass method years ended december millions except per share data basic eps net earnings earnings allocated participating securities earnings available common shareholders weightedaverage basic shares outstanding basic earnings per share diluted eps net earnings earnings allocated participating securities earnings available common shareholders weightedaverage shares common stock outstanding effect dilutive securities weightedaverage diluted shares outstanding diluted earnings per share certain shares issuable stockbased compensation plans excluded computation eps effect would antidilutive number common shares excluded insignificant periods presented note licensing acquisitions arrangements proposed acquisition allergan plc june abbvie announced entered definitive transaction agreement abbvie acquire allergan plc allergan cash stock transaction transaction equity value approximately billion based closing price abbvies common stock june terms transaction agreement allergan shareholders receive abbvie shares cash allergan share october allergan shareholders approved proposed transaction allergan global pharmaceutical leader focused developing manufacturing commercializing branded pharmaceutical device biologic surgical regenerative medicine products patients around world allergan markets portfolio brands products primarily focused key therapeutic areas including aesthetics eye care neuroscience gastroenterology women 's health transaction subject customary closing conditions regulatory approvals september abbvie allergan received request additional information second request federal trade commission ftc connection transaction abbvie allergan cooperating fully ftc january european commission approved proposed acquisition allergan abbvie conditional upon divestiture brazikumab allergan 's il inhibitor pipeline product january allergan entered definitive agreement divest brazikumab contingent upon regulatory approvals closing abbvie 's acquisition allergan anticipation proposed acquisition abbvie entered several debt financing arrangements see note additional information licensing acquisitions activity cash outflows related acquisitions investments totaled billion million million abbvie recorded acquired iprd charges million million million significant arrangements impacting require contingent milestone payments summarized form kreata pharmaceuticals inc october abbvie reata pharmaceuticals inc reata entered amended restated license agreement terms agreement reata reacquired exclusive development manufacturing commercialization rights concerning proprietary nrf activator product platform originally licensed abbvie territories outside united states respect bardoxolone methyl worldwide respect omaveloxolone nextgeneration nrf activators consideration rights reacquired reata abbvie receive total million cash payable three installments recognized operating expense income fourth quarter addition abbvie receive low single digit tiered royalties worldwide sales omaveloxolone certain nextgeneration nrf activators calico life sciences llc june abbvie calico life sciences llc calico entered extension collaboration discover develop bring market new therapies patients agerelated diseases including neurodegeneration cancer terms agreement abbvie calico contribute additional million collaboration term extended additional three years calico responsible research early development advance collaboration projects phase following completion phase abbvie option exclusively license collaboration compounds abbvie support calico early research development efforts upon exercise would responsible latestage development commercial activities collaboration costs profits shared equally parties post option exercise abbvie recorded million operating expense income consolidated statement earnings related commitments agreement alector inc october abbvie entered global strategic collaboration alector inc alector develop commercialize medicines treat alzheimers disease neurodegenerative disorders abbvie alector agreed research portfolio antibody targets abbvie option global development commercial rights two targets terms arrangement included initial upfront payment million expensed iprd fourth quarter alector conduct exploratory research drug discovery development lead programs conclusion proof concept studies option exercised abbvie lead development commercialization activities could make additional payments alector million upon achievement certain development regulatory milestones alector abbvie cofund development commercialization share global profits equally arrangements addition significant arrangements described abbvie entered several arrangements resulting charges iprd million million million connection individually insignificant earlystage arrangements entered abbvie could make additional payments billion upon achievement certain development regulatory commercial milestones note collaboration janssen biotech inc december pharmacyclics whollyowned subsidiary abbvie entered worldwide collaboration license agreement janssen biotech inc affiliates janssen one janssen pharmaceutical companies johnson johnson joint development commercialization imbruvica novel orally active selective covalent inhibitor bruton 's tyrosine kinase btk certain compounds structurally related imbruvica oncology indications excluding immune inflammatory mediated diseases conditions psychiatric psychological diseases conditions united states outside united states collaboration provides janssen exclusive license commercialize imbruvica outside united states coexclusively abbvie united states parties responsible development manufacturing marketing products generated result collaboration collaboration set duration specific expiration date provides potential future development regulatory approval milestone payments million abbvie collaboration also includes cost sharing arrangement associated collaboration activities except certain cases janssen responsible approximately collaboration development costs abbvie responsible remaining collaboration development costs united states parties coexclusive rights commercialize products however abbvie principal endcustomer product sales abbvie janssen share pretax profits losses equally commercialization products sales imbruvica included abbvie 's net revenues janssen 's share profits included abbvie 's cost products sold costs incurred collaboration reported respective expense line items net janssen 's share outside united states janssen responsible exclusive rights commercialize imbruvica abbvie janssen share pretax profits losses equally commercialization products abbvie 's share profits included abbvie 's net revenues costs incurred collaboration reported respective expense line items net janssen 's share following table shows profit cost sharing relationship janssen abbvie years ended december millions united states janssen 's share profits included cost products sold international abbvie 's share profits included net revenues global abbvie 's share costs included respective line items abbvies receivable janssen included accounts receivable net million december million december abbvies payable janssen included accounts payable accrued liabilities million december million december note goodwill intangible assets goodwill following table summarizes changes carrying amount goodwill millions balance december foreign currency translation balance december foreign currency translation balance december company performs annual goodwill impairment assessment third quarter earlier impairment indicators exist december accumulated goodwill impairment losses intangible assets net following table summarizes intangible assets gross net gross net carrying accumulated carrying carrying accumulated carrying december millions amount amortization amount amount amortization amount definitelived intangible assets developed product rights license agreements total definitelived intangible assets indefinitelived research development total intangible assets net form kindefinitelived intangible assets indefinitelived intangible assets represent acquired iprd associated products yet received regulatory approval company performs annual impairment assessment indefinitelived intangible assets third quarter earlier impairment indicators exist april us food drug administration fda european commission approved skyrizi risankizumab treatment moderate severe plaque psoriasis result abbvie reclassified billion indefinitelived intangible assets related skyrizi developed product rights definitelived intangible assets amount amortized estimated useful life using estimated pattern economic benefit fourth quarter company made decision stop enrollment tahoe trial phase study evaluating rovalpituzumab tesirine rovat secondline therapy advanced smallcell lung cancer following recommendation independent data monitoring committee decision lowered probabilities success achieving regulatory approval across rovat earlystage assets represented triggering event required company evaluate impairment iprd assets associated stemcentrx acquisition company utilized multiperiod excess earnings models income approach determined fair value billion december lower carrying value billion resulted impairment charge billion impairment charge recorded rd expense consolidated statement earnings year ended december third quarter following announcement decision terminate rovat research development program company recorded impairment charge billion represented remaining value iprd acquired part stemcentrx acquisition impairment charge recorded rd expense consolidated statement earnings year ended december indefinitelived intangible asset impairment charges recorded definitelived intangible assets definitelived intangible assets amortized estimated useful lives range years average years developed product rights license agreements amortization expense billion billion billion included cost products sold consolidated statements earnings anticipated annual amortization expense definitelived intangible assets recorded december follows billions anticipated annual amortization expense definitelived intangible asset impairment charges recorded impairment charge million recorded related zinbryta reduced gross carrying amount net carrying amount underlying intangible assets due lower expected future cash flows product impairment charge based discounted cash flow analyses included cost products sold consolidated statements earnings note restructuring plans abbvie continuously evaluates operations identify opportunities optimize manufacturing rd operations commercial infrastructure administrative costs respond changes business environment result abbvie management periodically approves individual restructuring plans achieve objectives plans individually significant restructuring charges recorded million million million primarily related employee severance contractual obligations charges recorded cost products sold rd expense sga expenses consolidated statements earnings based classification affected employees operations following table summarizes cash activity restructuring reserve millions accrued balance december restructuring charges payments adjustments accrued balance december restructuring charges payments adjustments accrued balance december restructuring charges payments adjustments accrued balance december note leases abbvie 's lease portfolio primarily consists real estate properties vehicles equipment following table summarizes amounts location operating finance leases consolidated balance sheet december millions balance sheet caption assets operating assets finance property equipment net total lease assets liabilities operating current accounts payable accrued liabilities noncurrent longterm liabilities finance current current portion longterm debt finance lease obligations noncurrent longterm debt finance lease obligations total lease liabilities following table summarizes lease costs recognized consolidated statement earnings year ended december millions operating lease cost shortterm lease cost variable lease cost total lease cost sublease income finance lease costs insignificant lease expense prior adoption asu million million form kthe following table presents weightedaverage remaining lease term weightedaverage discount rate operating finance leases december weightedaverage remaining lease term years operating finance weightedaverage discount rate operating finance following table presents supplementary cash flow information regarding company 's leases year ended december millions cash paid amounts included measurement lease liabilities operating cash flows operating leases rightofuse assets obtained exchange new operating lease liabilities finance lease cash flows insignificant following table summarizes future maturities abbvie 's operating finance lease liabilities december operating finance millions leases leases total ab thereafter total lease payments less interest present value lease liabilities total lease payments exclude approximately million contractual minimum lease payments leases executed yet commenced leases commence lease terms approximately years b lease payments recognized part lease liabilities optional renewal periods insignificant future minimum lease payments noncancelable operating leases capital leases december prior adoption asu differ materially future lease payments inclusive payments leases executed yet commenced new standard note debt credit facilities commitments contingencies following table summarizes longterm debt effective effective interest rate interest rate december dollars millions senior notes issued notes due notes due senior notes issued notes due notes due notes due notes due notes due senior notes issued notes due notes due notes due notes due notes due senior euro notes issued notes due principal notes due principal notes due principal senior notes issued notes due notes due notes due notes due senior euro notes issued notes due principal notes due principal senior notes issued floating rate notes due may floating rate notes due november floating rate notes due notes due notes due notes due notes due notes due notes due notes due fair value hedges unamortized bond discounts unamortized deferred financing costs total longterm debt finance lease obligations current portion noncurrent portion excludes effect related interest rate swaps form kallerganrelated financing connection proposed acquisition allergan november company issued billion aggregate principal amount unsecured senior notes consisting million aggregate principal amount floating rate senior notes due may million aggregate principal amount floating rate senior notes due november million aggregate principal amount floating rate senior notes due billion aggregate principal amount senior notes due billion aggregate principal amount senior notes due billion aggregate principal amount senior notes due billion aggregate principal amount senior notes due billion aggregate principal amount senior notes due billion aggregate principal amount senior notes due billion aggregate principal amount senior notes due senior notes rank equally unsecured unsubordinated indebtedness company abbvie may redeem fixedrate senior notes prior maturity redemption price equal greater principal amount sum present values remaining scheduled payments principal interest fixedrate senior notes redeemed plus makewhole premium exception fixedrate notes due abbvie may also redeem fixedrate senior notes par one six months prior maturity connection offering debt issuance costs incurred totaled million debt discounts totaled million amortized respective terms notes interest expense net consolidated statements earnings abbvie expects use net proceeds fund portion aggregate cash consideration due allergan shareholders connection proposed acquisition described note pay related fees expenses pending consummation proposed allergan acquisition net proceeds offering permitted invested temporarily shortterm investments notes subject special mandatory redemption redemption price equal aggregate principal amount notes plus accrued unpaid interest proposed acquisition allergan completed january company notifies trustee respect notes pursue consummation proposed allergan acquisition june abbvie entered billion day bridge credit agreement july abbvie entered term loan credit agreement aggregate principal amount billion consisting billion day term loan tranche billion threeyear term loan tranche billion fiveyear term loan tranche connection agreements debt issuance costs incurred totaled million recorded interest expense net consolidated statements earnings upon commencement billion term loan credit agreement upon issuance billion aggregate principal amount senior notes commitments bridge credit agreement reduced billion amounts drawn bridge credit agreement term loan credit agreement december february remaining commitments bridge credit agreement reduced result cash hand abbvie abbvie subsequently terminated bridge credit agreement entirety permitted terms october abbvie commenced offers exchange outstanding notes certain series issued allergan billion aggregate principal amount billion aggregate principal amount new notes issued abbvie cash subject conditions including closing pending acquisition allergan concurrently offers exchange allergan notes abbvie notes company solicited consents adopt certain proposed amendments indentures governing allergan notes among things eliminate substantially restrictive covenants indentures november company announced requisite number consents received adopt proposed amendments respect allergan notes allergan executed supplemental indenture respect allergan indenture implementing amendments become operative upon settlement exchange offers expiration exchange offers expected occur closing date abbvies acquisition allergan longterm debt september company issued billion aggregate principal amount unsecured senior euro notes consisting million aggregate principal amount senior notes due million aggregate principal amount senior notes due senior notes rank equally unsecured unsubordinated indebtedness company abbvie may redeem senior notes prior maturity redemption price equal principal amount senior notes redeemed plus makewhole premium may redeem senior notes par one three months prior maturity connection offering debt issuance costs incurred totaled million debt discounts totaled million amortized respective terms notes interest expense net consolidated statements earnings october company used proceeds redeem billion aggregate principal amount senior euro notes due mature november september company issued billion aggregate principal amount unsecured senior notes consisting billion aggregate principal amount senior notes due billion aggregate principal amount senior notes due billion aggregate principal amount senior notes due billion aggregate principal amount senior notes due senior notes rank equally unsecured unsubordinated indebtedness company abbvie may redeem senior notes prior maturity redemption price equal principal amount senior notes redeemed plus makewhole premium except notes due abbvie may redeem senior notes par one six months prior maturity connection offering debt issuance costs incurred totaled million debt discounts totaled million amortized respective terms senior notes interest expense net consolidated statements earnings billion net proceeds billion used repay company 's outstanding threeyear term loan credit agreement september billion used repay aggregate principal amount senior notes maturity november company used remaining proceeds repay term loan obligations became due may company also repaid billion aggregate principal amount senior notes maturity abbvie outstanding billion aggregate principal amount unsecured senior euro notes issued abbvie may redeem senior notes prior maturity redemption price equal principal amount senior notes redeemed plus makewhole premium abbvie may redeem senior notes par one three months prior maturity abbvie outstanding billion aggregate principal amount unsecured senior notes issued billion aggregate principal amount unsecured senior notes issued abbvie may redeem senior notes time prior maturity redemption price equal principal amount senior notes redeemed plus makewhole premium abbvie may redeem senior notes par one six months prior maturity abbvie outstanding billion aggregate principal amount unsecured senior notes issued abbvie may redeem senior notes series time senior notes series time time redemption price equal principal amount senior notes redeemed plus makewhole premium december company compliance senior note covenants term loan covenants shortterm borrowings shortterm borrowings included commercial paper borrowings million december commercial paper borrowings december weightedaverage interest rate commercial paper borrowings august abbvie entered amended restated billion fiveyear revolving credit facility matures august amended facility enables company borrow funds unsecured basis variable interest rates contains various covenants company compliance december commitment fees abbvie 's revolving credit facilities insignificant amounts outstanding company 's credit facilities december december march abbvie repaid billion day term loan credit agreement drawn june scheduled mature june maturities longterm debt following table summarizes abbvie 's debt maturities december years ending december millions thereafter total obligations commitments fair value hedges unamortized bond discounts deferred financing costs finance lease obligations total longterm debt finance lease obligations form kcontingencies guarantees connection separation abbvie indemnified abbott liabilities resulting operation abbvie 's business income tax liabilities respect periods prior distribution date liabilities agreed abbvie abbott abbvie material exposures offbalance sheet arrangements specialpurpose entities ordinary course business abbvie periodically entered thirdparty agreements assignment product rights resulted abbvie becoming secondarily liable obligations abbvie previously primarily liable based upon past experience likelihood payments agreements remote note financial instruments fair value measures risk management policy company exposed foreign currency exchange rate interest rate risks related business operations abbvie 's hedging policy attempts manage risks acceptable level based company 's judgment appropriate tradeoff risk opportunity costs company uses derivative nonderivative instruments reduce exposure foreign currency exchange rates abbvie also periodically enters interest rate swaps company agrees exchange specified intervals difference fixed floating interest amounts calculated reference agreed upon notional amount derivative instruments used trading purposes manage exposure changes interest rates investment securities none company 's outstanding derivative instruments contain credit risk related contingent features collateral generally required financial instruments various abbvie foreign subsidiaries enter foreign currency forward exchange contracts manage exposures changes foreign exchange rates anticipated intercompany transactions denominated currency functional currency local entity contracts notional amounts totaling million december billion december designated cash flow hedges recorded fair value durations forward exchange contracts generally less eighteen months accumulated gains losses december reclassified aoci included cost products sold time products sold generally exceeding six months date settlement third quarter company entered treasury rate lock agreements notional amounts totaling billion hedge exposure variability future cash flows resulting changes interest rates related issuance longterm debt connection proposed acquisition allergan treasury rate lock agreements designated cash flow hedges recorded fair value agreements net settled upon issuance senior notes november resulting gain million recognized comprehensive income loss gain reclassified interest expense net lives related debt fourth quarter company entered interest rate swap contracts notional amounts totaling billion december effect hedge contracts change floatingrate interest obligation fixed rate portion floatingrate debt contracts designated cash flow hedges recorded fair value realized unrealized gains losses included aoci reclassified interest expense net lives floatingrate debt company also enters foreign currency forward exchange contracts manage exposure foreign currency denominated trade payables receivables intercompany loans contracts designated hedges recorded fair value resulting gains losses reflected net foreign exchange loss consolidated statements earnings generally offset losses gains foreign currency exposure managed contracts notional amounts totaling billion december billion december company also uses foreign currency forward exchange contracts foreign currency denominated debt hedge net investments certain foreign subsidiaries affiliates company billion aggregate principal amount senior euro notes designated net investment hedges december december third quarter company issued billion aggregate principal amount senior euro notes designated principal amounts foreign denominated debt net investment hedges concurrently company elected dedesignate hedge accounting billion aggregate principal amount existing senior euro notes subsequently repaid october addition company entered foreign currency forward exchange contracts designated instruments net investment hedges contracts notional amounts totaling million million chf million december company uses spot method assessing hedge effectiveness derivative instruments designated net investment hedges realized unrealized gains losses hedges included aoci initial fair value hedge components excluded assessment effectiveness recognized interest expense net life hedging instrument abbvie party interest rate swap contracts designated fair value hedges notional amounts totaling billion december december effect hedge contracts change fixedrate interest obligation floating rate portion debt abbvie records contracts fair value adjusts carrying amount fixedrate debt offsetting amount amounts excluded assessment effectiveness cash flow hedges fair value hedges following table summarizes amounts location abbvie 's derivative instruments consolidated balance sheets fair value fair value derivatives asset position derivatives liability position december millions balance sheet caption balance sheet caption foreign currency forward exchange contracts accounts payable designated cash flow hedges prepaid expenses accrued liabilities accounts payable designated net investment hedges prepaid expenses accrued liabilities accounts payable designated hedges prepaid expenses accrued liabilities interest rate swap contracts designated cash flow hedges assets longterm liabilities accounts payable designated fair value hedges prepaid expenses accrued liabilities designated fair value hedges assets longterm liabilities total derivatives certain derivatives subject netting arrangements company 's counterparties company offset derivative assets liabilities within consolidated balance sheets following table presents pretax amounts gains losses derivative instruments recognized comprehensive income loss years ended december millions foreign currency forward exchange contracts designated cash flow hedges designated net investment hedges interest rate swap contracts designated cash flow hedges treasury rate lock agreements designated cash flow hedges assuming market rates remain constant contract maturities company expects transfer pretax losses million cost products sold foreign currency cash flow hedges pretax gains million interest expense net interest rate swap cash flow hedges pretax gains million interest expense net treasury rate lock agreement cash flow hedges next months related abbvies nonderivative foreign currency denominated debt designated net investment hedges company recognized comprehensive income loss pretax gains million pretax gains million pretax losses million form kthe following table summarizes pretax amounts location derivative instrument net gains losses recognized consolidated statements earnings including net gains losses reclassified aoci net earnings see note amount net gains losses reclassified aoci years ended december millions statement earnings caption foreign currency forward exchange contracts designated cash flow hedges cost products sold designated net investment hedges interest expense net designated hedges net foreign exchange loss treasury rate lock agreements designated cash flow hedges interest expense net interest rate swap contracts designated cash flow hedges interest expense net designated fair value hedges interest expense net debt designated hedged item fair value hedges interest expense net fair value measures fair value hierarchy consists following three levels level valuations based unadjusted quoted prices active markets identical assets company ability access level valuations based quoted prices similar instruments active markets quoted prices identical similar instruments markets active modelbased valuations significant inputs observable market level valuations using significant inputs unobservable market include use judgment company 's management assumptions market participants would use pricing asset liability following table summarizes bases used measure certain assets liabilities carried fair value recurring basis consolidated balance sheet december basis fair value measurement quoted prices active significant significant markets observable unobservable identical assets inputs inputs millions total level level level assets cash equivalents debt securities equity securities interest rate swap contracts foreign currency contracts total assets liabilities interest rate swap contracts foreign currency contracts contingent consideration total liabilities following table summarizes bases used measure certain assets liabilities carried fair value recurring basis consolidated balance sheet december basis fair value measurement quoted prices active significant significant markets observable unobservable identical assets inputs inputs millions total level level level assets cash equivalents time deposits debt securities equity securities foreign currency contracts total assets liabilities interest rate swap contracts foreign currency contracts contingent consideration total liabilities fair values time deposits approximate amortized cost due short maturities instruments fair values availableforsale debt securities determined based prices obtained commercial pricing services derivatives entered company valued using observable market inputs including published interest rate curves forward spot prices foreign currencies fair value measurements contingent consideration liabilities determined based significant unobservable inputs including discount rate estimated probabilities timing achieving specified development regulatory commercial milestones estimated amount future sales acquired products potential contingent consideration payments estimated applying probabilityweighted expected payment model contingent milestone payments monte carlo simulation model contingent royalty payments discounted present value changes fair value contingent consideration liabilities result changes one number inputs including discount rates probabilities achieving milestones time required achieve milestones estimated future sales significant judgment employed determining appropriateness certain inputs changes inputs described could material impact company 's financial position results operations given period december basis point increasedecrease assumed discount rate would decreasedincreased value contingent consideration liabilities approximately million additionally december five percentage point increasedecrease assumed probability success across potential indications would increaseddecreased value contingent consideration liabilities approximately million transfers assets liabilities fair value measurement levels following table presents changes fair value contingent consideration liabilities measured using level inputs years ended december millions beginning balance change fair value recognized net earnings payments ending balance change fair value recognized net earnings recorded expense net consolidated statements earnings second quarter company recorded billion increase skyrizi contingent consideration liability due higher probabilities success higher estimated future sales declining interest rates higher probabilities success resulted april regulatory approvals skyrizi treatment moderate severe plaque psoriasis third quarter company recorded million decrease stemcentrx contingent consideration liability due termination rovat research development program fourth quarter company recorded million decrease stemcentrx contingent consideration liability due reduction probabilities success achieving regulatory approval form kcertain financial instruments carried historical cost basis fair value book values approximate fair values bases used measure approximate fair values certain financial instruments december shown table basis fair value measurement quoted prices significant significant active markets observable unobservable approximate identical assets inputs inputs millions book value fair values level level level liabilities current portion longterm debt finance lease obligations excluding fair value hedges longterm debt finance lease obligations excluding fair value hedges total liabilities book values approximate fair values bases used measure approximate fair values certain financial instruments december shown table basis fair value measurement quoted prices significant significant active markets observable unobservable approximate identical assets inputs inputs millions book value fair values level level level liabilities shortterm borrowings current portion longterm debt finance lease obligations excluding fair value hedges longterm debt finance lease obligations excluding fair value hedges total liabilities abbvie also holds investments equity securities readily determinable fair values company records investments cost remeasures fair value based certain observable price changes impairment events occur carrying amount investments million december million december significant cumulative upward downward adjustments recorded investments december availableforsale securities substantially companys investments debt securities classified availableforsale changes fair value recognized comprehensive income third quarter company sold substantially investments debt securities debt securities classified shortterm december million december longterm debt securities mature primarily within five years estimated fair values availableforsale debt securities based prices obtained commercial pricing services following table summarizes availableforsale securities type december gross unrealized millions amortized cost gains losses fair value asset backed securities corporate debt securities debt securities total abbvie otherthantemporary impairments december net realized gains losses insignificant net realized gains million concentrations risk company invests excess cash time deposits money market funds debt securities diversify concentration cash among different financial institutions company established credit exposure limits monitors concentrations credit risk associated financial institution deposits total net accounts receivable three us wholesalers accounted december december substantially abbvie 's net revenues united states three wholesalers humira adalimumab abbvie 's single largest product accounted approximately abbvie 's total net revenues note postemployment benefits abbvie sponsors various pension postemployment benefit plans including defined benefit defined contribution termination indemnity plans cover employees worldwide addition abbvie provides medical benefits primarily eligible retirees united states puerto rico postretirement benefit plans net obligations plans reflected consolidated balance sheets december following table summarizes benefit plan information global abbviesponsored defined benefit postemployment plans defined benefit plans postemployment plans years ended december millions projected benefit obligations beginning period service cost interest cost employee contributions actuarial gain loss benefits paid primarily foreign currency translation adjustments end period fair value plan assets beginning period actual return plan assets company contributions employee contributions benefits paid primarily foreign currency translation adjustments end period funded status end period amounts recognized consolidated balance sheets assets accounts payable accrued liabilities longterm liabilities net obligation actuarial loss net prior service cost credit accumulated comprehensive loss actuarial losses table primarily driven lower discount rates form kthe projected benefit obligations pbo table included billion december billion december related international defined benefit plans plans reflected table accumulated benefit obligations abo billion december billion december plans reflected table abo exceeded plan assets december abo billion pbo billion aggregate plan assets billion amounts recognized comprehensive income loss following table summarizes pretax losses gains included comprehensive income loss years ended december millions defined benefit plans actuarial loss amortization actuarial loss prior service cost foreign exchange loss gain total loss postemployment plans actuarial loss gain amortization actuarial loss prior service credit total loss gain pretax amounts included aoci december expected recognized net periodic benefit cost consisted million expense related actuarial losses prior service costs defined benefit plans million income related actuarial losses prior service credits postemployment plans net periodic benefit cost years ended december millions defined benefit plans service cost interest cost expected return plan assets amortization actuarial loss prior service cost net periodic benefit cost postemployment plans service cost interest cost amortization actuarial loss prior service credit net periodic benefit cost components net periodic benefit cost service cost included expense net consolidated statements earnings weightedaverage assumptions used determining benefit obligations measurement date december defined benefit plans discount rate rate compensation increases postemployment plans discount rate assumptions used calculating december measurement date benefit obligations used calculation net periodic benefit cost weightedaverage assumptions used determining net periodic benefit cost years ended december defined benefit plans discount rate determining service cost discount rate determining interest cost expected longterm rate return plan assets expected rate change compensation postemployment plans discount rate determining service cost discount rate determining interest cost december postretirement health care obligations remeasurement company assumed pre post annual rate increase per capita cost covered health care benefits rate assumed decrease gradually remain level thereafter purposes measuring postretirement health care costs company assumed pre post annual rate increase per capita cost covered health care benefits rate assumed decrease gradually remain level thereafter assumed health care cost trend rates significant effect amounts reported health care plans december one percentage point change assumed health care cost trend rates would following effects one percentage point year ended december millions brackets denote reduction increase decrease service cost interest cost projected benefit obligation defined benefit pension plan assets basis fair value measurement quoted prices active significant significant markets observable unobservable identical assets inputs inputs december millions level level level equities us large capa us mid capb internationalc fixed income securities us government securitiesd corporate debt instrumentsd nonus government securitiesd otherd absolute return fundse real assets otherf total total assets measured nav fair value plan assets form kbasis fair value measurement quoted prices active significant significant markets observable unobservable identical assets inputs inputs december millions level level level equities us large capa us mid capb internationalc fixed income securities us government securitiesd corporate debt instrumentsd nonus government securitiesd otherd absolute return fundse real assets otherf total total assets measured nav fair value plan assets mix index funds actively managed equity accounts benchmarked various large cap indices b mix index funds actively managed equity accounts benchmarked various mid cap indices c mix index funds actively managed equity accounts benchmarked various nonus equity indices developed emerging markets securities held actively managed accounts index funds mutual funds e primarily funds global mandates flexibility allocate capital broadly across wide range asset classes strategies including limited equities fixed income commodities financial futures currencies securities objectives outperform agreed upon benchmarks specific return volatility targets f investments cash cash equivalents equities registered investment companies quoted prices valued published market prices fixed income securities valued using significant observable inputs quoted prices obtained independent financial service industryrecognized vendors investments held pooled investment funds common collective trusts limited partnerships valued net asset value nav practical expedient estimate fair value nav provided fund administrator based value underlying assets owned fund minus liabilities investment mix equity securities fixed income asset allocation strategies based upon achieving desired return balancing higher return volatile equity securities lower return less volatile fixed income securities investment allocations established plan generally made across range markets industry sectors capitalization sizes case fixed income securities maturities credit quality target investment allocation abbvie pension plan equity securities fixed income securities asset allocation strategies holdings known significant concentrations risk plan assets abbvie pension plan plans expected return plan assets assumption plan based management 's expectations longterm average rates return achieved underlying investment portfolio establishing assumption management considers historical expected returns asset classes plans invested well current economic capital market conditions expected benefit payments following table summarizes total benefit payments expected paid plan participants including payments funded plan company assets defined postemployment years ending december millions benefit plans plans defined contribution plan abbvie 's principal defined contribution plan abbvie savings plan abbvie recorded expense million million million related plan abbvie provides certain postemployment benefits primarily salary continuation arrangements qualifying employees accrues related cost service lives employees note equity stockbased compensation abbvie grants stockbased awards eligible employees pursuant abbvie incentive stock program isp provides several different forms benefits including nonqualified stock options rsus various performancebased awards isp million shares abbvie common stock reserved issuance awards abbvie employees isp also facilitated assumption certain awards granted abbotts incentive stock program adjusted converted abbott abbvie stockbased awards result abbvie 's separation abbott abbvie measures compensation expense stockbased awards based grant date fair value awards estimated number awards expected vest forfeitures estimated based historical experience time grant revised subsequent periods actual forfeitures differ estimates compensation cost stockbased awards amortized service period could shorter vesting period employee retirement eligible retirement eligible employees generally age older least years service stockbased compensation expense principally related awards issued pursuant isp summarized follows years ended december millions cost products sold research development selling general administrative pretax compensation expense tax benefit aftertax compensation expense realized excess tax benefits associated stockbased compensation totaled million million million form kstock options stock options awarded employees typically contractual term years generally vest onethird increments threeyear period exercise price equal least market value date grant fair value determined using blackscholes model weighted average grantdate fair values stock options granted following table summarizes abbvie stock option activity weighted weighted average average remaining aggregate options thousands aggregate intrinsic value millions options exercise price life years intrinsic value outstanding december granted exercised lapsed outstanding december exercisable december total intrinsic value options exercised million million million total fair value options vested million december million unrecognized compensation cost related stock options expected recognized expense approximately next two years rsus performance shares rsus awarded employees senior executives key employees generally vest onethird increments three year period recipients rsus entitled receive dividend equivalents dividends declared paid rsu vesting period majority equity awards abbvie grants senior executives key employees performancebased equity awards granted senior executives key employees consist combination performancevested rsus performance shares well nonqualified stock options described performancevested rsus potential vest onethird increments threeyear performance period based abbvies roe relative defined peer group pharmaceutical biotech life sciences companies recipient may receive one share abbvie common stock vested award performance shares potential vest threeyear performance period may earned based abbvies eps achievement abbvies total stockholder return tsr market condition relative defined peer group pharmaceutical biotech life sciences companies dividend equivalents performancevested rsus performance shares accrue performance period payable vesting extent shares earned weightedaverage grantdate fair value rsus performance shares generally determined based number sharesunits granted quoted price abbvies common stock date grant weightedaverage grantdate fair values performance shares tsr market condition determined using monte carlo simulation model following table summarizes abbvie rsu performance share activity weightedaverage share units thousands share units grant date fair value outstanding december granted vested forfeited outstanding december fair market value rsus performance shares applicable vested million million million december million unrecognized compensation cost related rsus performance shares expected recognized expense approximately next two years cash dividends cash dividends declared per common share totaled following table summarizes quarterly cash dividends declared date declared payment date dividend per share date declared payment date dividend per share date declared payment date dividend per share stock repurchase program company 's stock repurchase authorization permits purchases abbvie shares time time openmarket private transactions managements discretion program time limit discontinued time shares repurchased programs recorded acquisition cost including related expenses available general corporate purposes abbvie repurchased million shares million abbvie 's remaining stock repurchase authorization approximately billion december february abbvie 's board directors authorized new billion stock repurchase program superseded abbvie 's previous stock repurchase program december abbvie 's board directors authorized billion increase existing billion stock repurchase program authorization abbvie repurchased approximately million shares billion previous stock repurchase programs abbvie made openmarket share repurchases approximately million shares billion approximately million shares billion form kaccumulated comprehensive loss following table summarizes changes component accumulated comprehensive loss net tax foreign pension currency net investment post translation hedging employment marketable security cash flow hedging millions brackets denote losses adjustments activities benefits activities activities total balance december comprehensive income loss reclassifications net losses gains reclassified accumulated comprehensive loss net currentperiod comprehensive income loss balance december comprehensive income loss reclassifications net losses reclassified accumulated comprehensive loss net currentperiod comprehensive income loss balance december comprehensive income loss reclassifications net losses gains reclassified accumulated comprehensive loss net currentperiod comprehensive income loss balance december comprehensive loss included foreign currency translation adjustments totaling losses million million principally due impact weakening euro translation companys eurodenominated assets abbvie reclassified million historical currency translation losses aoci related liquidation certain foreign entities following enactment us tax reform losses included net foreign exchange loss consolidated statement earnings related income tax impacts comprehensive loss also included foreign currency translation adjustments totaling gain million principally due impact strengthening euro translation companys eurodenominated assets comprehensive loss included pension postemployment benefit plan losses billion primarily due actuarial loss driven lower discount rates see note additional information table presents impact abbvie 's consolidated statements earnings significant amounts reclassified component accumulated comprehensive loss years ended december millions brackets denote gains net investment hedging activities gains derivative amount excluded effectiveness testinga tax expense total reclassifications net tax pension postemployment benefits amortization actuarial losses otherb tax benefit total reclassifications net tax cash flow hedging activities losses gains foreign currency forward exchange contractsc gains treasury rate lock agreements interest rate swap contractsa tax expense benefit total reclassifications net tax amounts included interest expense net see note b amounts included computation net periodic benefit cost see note c amounts included cost products sold see note addition common stock abbvie 's authorized capital includes million shares preferred stock par value december shares preferred stock issued outstanding note income taxes earnings income tax expense years ended december millions domestic foreign total earnings income tax expense income tax expense years ended december millions current domestic foreign total current taxes deferred domestic foreign total deferred taxes total income tax expense benefit form kimpacts related us tax reform tax cuts jobs act act signed law december resulting significant changes us corporate tax system act reduced us federal corporate tax rate required companies pay onetime transition tax mandatory deemed repatriation earnings certain foreign subsidiaries previously untaxed changes generally effective tax years beginning act also created minimum tax certain foreign sourced earnings companys accounting policy minimum tax foreign sourced earnings report tax effects basis minimum tax recognized tax expense year incurred period expense additionally act significantly changed timing manner earnings foreign subsidiaries subject us tax therefore unremitted foreign earnings previously considered indefinitely reinvested subject acts transition tax longer considered indefinitely reinvested post earnings subject us minimum tax foreign sourced earnings percent foreign dividends received deduction also considered indefinitely reinvested earnings company records foreign withholding tax liabilities related future cash repatriation earnings however company considers instances outside basis differences foreign subsidiaries would incur additional us tax upon reversal eg capital gain distribution permanent duration unrecognized tax liability practicable determine effective tax rate reconciliation years ended december statutory tax rate effect foreign operations us tax credits impacts related us tax reform stockbased compensation excess tax benefit tax audit settlements deferred tax remeasurements due change tax rate net effective tax rate effective income tax rate fluctuates year year due allocation company 's taxable earnings among jurisdictions well certain discrete factors events year including changes tax law acquisitions collaborations effective income tax rates differed statutory tax rate principally due changes enacted tax rates laws benefit foreign operations reflects impact lower income tax rates locations outside united states tax incentives puerto rico foreign tax jurisdictions business development activities cost repatriation decisions boehringer ingelheim accretion contingent consideration stemcentrx impairment related expenses effective tax rates periods also reflected benefit us tax credits principally related research development credits orphan drug tax credit puerto rico excise tax credits puerto rico excise tax credits relate legislation enacted puerto rico assesses excise tax certain products manufactured puerto rico tax levied gross inventory purchases entities puerto rico included cost products sold consolidated statements earnings majority tax creditable us income tax purposes effective income tax rate included impacts related us tax reform favorable impact effective date provisions act related earnings certain foreign subsidiaries impact act affected full year earnings subsidiaries resulting additional tax expense compared prior year effective income tax rate also reflects effects deferred tax remeasurement due change foreign tax law accretion contingent consideration impairment related expenses addition company recognized net tax benefit million million million related resolution various tax positions pertaining prior years deferred tax assets liabilities december millions deferred tax assets compensation employee benefits accruals reserves chargebacks rebates advance payments net operating losses credit carryforwards total deferred tax assets valuation allowances total net deferred tax assets deferred tax liabilities excess book basis tax basis intangible assets excess book basis tax basis investments total deferred tax liabilities net deferred tax liabilities december gross state net operating losses billion tax credit carryforwards million state tax carryforwards expire december foreign net operating loss carryforwards billion foreign net operating loss carryforwards billion expire remaining expiration period company valuation allowances million december million december principally related foreign state net operating losses credit carryforwards expected realized unrecognized tax benefits years ended december millions beginning balance increase due current year tax positions increase due prior year tax positions decrease due prior year tax positions settlements lapse statutes limitations ending balance abbvie abbott entered tax sharing agreement effective date separation provides abbott liable indemnified abbvie income tax liabilities periods prior separation abbvie responsible unrecognized tax benefits related interest penalties periods separation instances existing entity transferred abbvie upon separation recognized net amount potential tax benefits would impact company 's effective tax rate billion billion unrecognized tax benefits recorded table december abbvie would indemnified approximately million increase due current year tax positions increase due prior year tax positions table include amounts related federal state international tax items abbvie recognizes interest penalties related income tax matters income tax expense consolidated statements earnings abbvie recognized gross income tax expense million million million interest penalties related income tax matters abbvie accrual payment gross form kinterest penalties million december million december million december company routinely audited tax authorities significant jurisdictions number audits currently underway reasonably possible next months uncertain tax positions may settled could result decrease gross amount unrecognized tax benefits due potential resolution federal state foreign examinations expiration various statutes limitation company 's gross unrecognized tax benefits balance may change within next months million significant federal state local international matters concluded years company believes adequate provision made income tax uncertainties note legal proceedings contingencies abbvie subject contingencies various claims legal proceedings investigations regarding product liability intellectual property commercial securities matters arise normal course business loss contingency provisions recorded probable losses managements best estimate loss best estimate made minimum loss contingency amount within probable range recorded recorded accrual balance litigation approximately million december approximately million december initiation new legal proceedings change status existing proceedings may result change estimated loss accrued abbvie addition operating income included million income legal settlement related intellectual property dispute third party feasible predict outcome proceedings exposures certainty management believes ultimate disposition material adverse effect abbvies consolidated financial position results operations cash flows subject certain exceptions specified separation agreement abbott abbvie abbvie assumed liability control pending threatened legal matters related business including liabilities claims legal proceedings related products part business discontinued prior distribution well assumed retained liabilities indemnify abbott liability arising resulting assumed legal matters four lawsuits unimed pharmaceuticals llc solvay pharmaceuticals inc company abbott acquired february known abbvie products llc others remained consolidated pretrial purposes united states district court northern district georgia multi district litigation mdl rules androgel antitrust litigation mdl cases brought direct androgel purchasers generally allege solvay 's patent litigation settlement agreements related agreements three generic companies violate federal antitrust laws plaintiffs seek monetary damages attorneys ' fees three lawsuits settled december dismissed september ftc filed lawsuit ftc v abbvie inc et al abbvie others united states district court eastern district pennsylvania alleging patent litigation two generic companies regarding androgel sham litigation settlements litigation violated federal antitrust law may court dismissed ftcs settlementrelated claim june following bench trial court found ftc sham litigation claim ordered disgorgement remedy million plus prejudgment interest court denied ftcs request injunctive relief abbvie appealing courts liability disgorgement rulings based assessment merits appeal liability accrued matter ftc also appealing aspects courts trial ruling dismissal settlementrelated claim july purported class action filed united states district court eastern district pennsylvania behalf direct androgel purchasers based trial courts ruling ftcs case september two individual direct androgel purchasers substituted plaintiffs lawsuit withdrew class allegations case pending rochester drug cooperative inc et al v abbvie inc et al settled december dismissed august direct purchasers androgel filed lawsuit king drug co florence inc et al v abbvie inc et al abbvie others united states district court eastern district pennsylvania making allegations similar androgel antitrust litigation ii mdl ftc v abbvie inc lawsuits pending abbvie others generally alleging patent litigation settlement involving niaspan entered kos pharmaceuticals inc company acquired abbott presently subsidiary abbvie generic company violates federal state antitrust laws state unfair deceptive trade practices unjust enrichment laws plaintiffs generally seek monetary damages andor injunctive relief attorneys ' fees lawsuits consist four individual plaintiff lawsuits two consolidated purported class actions one brought niaspan direct purchasers one brought niaspan endpayers cases pending united states district court eastern district pennsylvania coordinated consolidated pretrial proceedings mdl rules niaspan antitrust litigation mdl august court certified class direct purchasers niaspan october orange county california district attorneys office filed lawsuit behalf state california regarding niaspan patent litigation settlement orange county superior court asserting claim unfair competition provision california business professions code seeking injunctive relief restitution civil penalties attorneys fees may california court appeal ruled district attorneys office may bring monetary claims beyond scope orange county district attorneys office appealing march may putative class action lawsuits filed united states district court northern district illinois indirect humira purchasers alleging abbvies settlements biosimilar manufacturers abbvies humira patent portfolio violate state federal antitrust laws court consolidated lawsuits humira adalimumab antitrust litigation november putative class action lawsuit medical mutual ohio v abbvie inc et al filed several manufacturers testosterone replacement therapies trts including abbvie united states district court northern district illinois behalf insurance companies health benefit providers third party payers paid trts including androgel claims asserted included violations federal rico act state consumer fraud deceptive trade practices laws complaint sought monetary damages injunctive relief july court denied plaintiffs motion class certification november united states court appeals seventh circuit affirmed district courts grant defendants summary judgment motion july new mexico attorney general filed lawsuit state new mexico ex rel balderas v abbvie inc et al new mexico district court santa fe county abbvie companies alleging marketing androgel violated new mexicos unfair practices act september commissioner california department insurance intervened qui tam lawsuit state california lazaro suarez v abbvie inc et al brought california insurance frauds prevention act california superior court alameda county department insurances complaint alleges patient reimbursement support services services items value provided connection humira abbvie caused submission fraudulent commercial insurance claims humira violation california statute complaint seeks injunctive relief assessment three times amount claims issue civil penalties addition federal securities lawsuit holwill v abbvie inc et al pending united states district court northern district illinois abbvie chief executive officer former chief financial officer alleging reasons stated humira sales growth financial filings misleading omitted conduct alleged department insurances complaint november five individuals filed putative class action lawsuit rubinstein et al v gonzalez et al behalf purchasers sellers certain shire plc shire securities june october abbvie chief executive officer united states district court northern district illinois alleging defendants made andor responsible material misstatements violation federal securities laws connection abbvie 's proposed transaction shire october court granted final approval parties class settlement agreement june lawsuit elliott associates lp et al v abbvie inc filed five investment funds abbvie cook county illinois circuit court alleging abbvie made misrepresentations omissions connection proposed transaction shire similar lawsuits filed july october abbvie instances chief executive officer court additional investment funds plaintiffs seek compensatory punitive damages product liability cases filed plaintiffs generally allege abbvie manufacturers trts adequately warn risks certain injuries primarily heart attacks strokes blood clots approximately claims abbvie consolidated pretrial purposes united states district court northern district illinois mdl rules testosterone replacement therapy products liability litigation mdl approximately claims abbvie pending various state courts plaintiffs generally seek compensatory punitive damages november abbvie entered master settlement agreement plaintiffs steering committee mdl encompassing existing claims courts proceedings pending cases effectively stayed settlement administration process product liability cases pending plaintiffs generally allege abbvie adequately warn risk certain injuries primarily various birth defects arising use depakote approximately cases pending united states district court southern district illinois approximately others pending various federal state courts plaintiffs generally seek compensatory punitive damages approximately eighty percent pending form kcases plus unfiled claims subject confidential settlement agreements expected dismissed prejudice beginning may patent trial appeal board us patent trademark office pto instituted five inter partes review proceedings brought coherus biosciences boehringer ingelheim related three abbvie patents covering methods treatment rheumatoid arthritis using adalimumab proceedings pto reviewed validity patents issued decisions invalidity may june july january court appeals federal circuit affirmed decisions march abbvie filed lawsuit abbvie inc v novartis vaccines diagnostics inc grifols worldwide operations ltd united states district court northern district california novartis vaccines grifols worldwide seeking declaratory judgment hcvrelated patents licensed abbvie invalid pharmacyclics llc wholly owned subsidiary abbvie seeking enforce patent rights relating ibrutinib capsules drug pharmacyclics sells trademark imbruvica february cases filed united states district court district delaware following defendants fresenius kabi usa llc fresenius kabi usa inc fresenius kabi oncology limited sun pharma global fze sun pharmaceutical industries ltd cipla limited cipla usa inc zydus worldwide dmcc cadila healthcare limited sandoz inc lek pharmaceuticals dd case pharmacyclics alleges defendants proposed generic ibrutinib product infringes certain pharmacyclics patents seeks declaratory injunctive relief janssen biotech inc global collaboration pharmacyclics concerning development marketing imbruvica coplaintiff suits pharmacyclics llc wholly owned subsidiary abbvie seeking enforce patent rights relating ibrutinib tablets drug pharmacyclics sells trademark imbruvica case filed united states district court district delaware march pharmacyclics alleges alvogen pine brook llcs natco pharma ltds proposed generic ibrutinib tablet product infringes certain pharmacyclics patents pharmacyclics seeks declaratory injunctive relief janssen biotech inc global collaboration pharmacyclics concerning development marketing imbruvica coplaintiff suit note segment geographic area information abbvie operates one business segmentpharmaceutical products substantially abbvie 's net revenues united states three wholesalers outside united states products sold primarily health care providers distributors depending market served following tables detail abbvie 's worldwide net revenues years ended december millions immunology humira united states international total skyrizi united states international total rinvoq united states international total hematologic oncology imbruvica united states collaboration revenues total venclexta united states international total hcv mavyret united states international total viekira united states international total key products creon united states lupron united states international total synthroid united states synagis international duodopa united states international total sevoflurane united states international total kaletra united states international total androgel united states orilissa united states international total total net revenues form knet revenues external customers geographic area based product shipment destination follows years ended december millions united states japan germany canada france spain united kingdom italy brazil netherlands countries total net revenues longlived assets primarily net property equipment geographic area follows december millions united states puerto rico europe total longlived assets note quarterly financial data unaudited millions except per share data first quarter net revenues gross margin net earningsa basic earnings per share diluted earnings per share cash dividends declared per common share second quarter net revenues gross margin net earningsb basic earnings per share diluted earnings per share cash dividends declared per common share third quarter net revenues gross margin net earningsc basic earnings per share diluted earnings per share cash dividends declared per common share fourth quarter net revenues gross margin net earnings lossd basic earnings loss per share diluted earnings loss per share cash dividends declared per common share first quarter results included aftertax charges million related change fair value contingent consideration liabilities restructuring charges million first quarter results included aftertax benefit million related change fair value contingent consideration liabilities partially offset aftertax litigation reserves charges million b second quarter results included aftertax charge billion related change fair value contingent consideration liabilities resulting april regulatory approvals skyrizi treatment moderate severe plaque psoriasis second quarter results included aftertax charges million result collaboration agreement extension calico million related change fair value contingent consideration liabilities c third quarter results included aftertax charges million related intangible asset impairment million related change fair value contingent consideration liabilities third quarter results included aftertax litigation reserves charges million million related change fair value contingent consideration liabilities fourth quarter results included aftertax charge million related change fair value contingent consideration liabilities offset aftertax income million legal settlement related intellectual property dispute third party million amended restated license agreement abbvie reata fourth quarter results included aftertax intangible asset impairment charge billion partially offset aftertax benefit million related change fair value contingent consideration liabilities report independent registered public accounting firm stockholders board directors abbvie inc opinion financial statements audited accompanying consolidated balance sheets abbvie inc subsidiaries company december related consolidated statements earnings comprehensive income equity cash flows three years period ended december related notes collectively referred financial statements opinion financial statements present fairly material respects financial position company december results operations cash flows three years period ended december conformity us generally accepted accounting principles also audited accordance standards public company accounting oversight board united states pcaob company 's internal control financial reporting december based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission framework report dated february expressed unqualified opinion thereon basis opinion financial statements responsibility company 's management responsibility express opinion company 's financial statements based audits public accounting firm registered pcaob required independent respect company accordance us federal securities laws applicable rules regulations securities exchange commission pcaob conducted audits accordance standards pcaob standards require plan perform audit obtain reasonable assurance whether financial statements free material misstatement whether due error fraud audits included performing procedures assess risks material misstatement financial statements whether due error fraud performing procedures respond risks procedures included examining test basis evidence regarding amounts disclosures financial statements audits also included evaluating accounting principles used significant estimates made management well evaluating overall presentation financial statements believe audits provide reasonable basis opinion critical audit matters critical audit matters communicated matters arising current period audit financial statements communicated required communicated audit committee relate accounts disclosures material financial statements involved especially challenging subjective complex judgments communication critical audit matters alter way opinion financial statements taken whole communicating critical audit matters providing separate opinions critical audit matters accounts disclosures relate form ksales rebate accruals medicaid medicare managed care programs description matter discussed note consolidated financial statements caption revenue recognition company established provisions sales rebates period related product sold december company million sales rebate accruals large portion rebates provided pharmacy benefit managers state government medicaid programs insurance companies administer medicare drug plans private entities medicaid medicare managed care programs order establish sales rebate accruals company estimated rebates based upon identification products subject rebate applicable price rebate terms estimated lag time sale payment rebate auditing medicaid medicare managed care sales rebate accruals complex required significant auditor judgment accruals consider multiple subjective complex estimates assumptions estimates assumptions included estimated inventory distribution channel impacts lag time sale customer payment rebate final payer related product sales impacts applicable price rebate terms deriving estimates assumptions company used internal external sources information estimate product distribution channels payer mix prescription volumes historical experience management supplemented historical data analysis qualitative adjustments based upon changes rebate trends rebate programs contract terms legislative changes significant events indicate change reserve appropriate addressed obtained understanding evaluated design tested operating effectiveness controls companys matter audit sales rebate accruals medicaid medicare managed care programs included testing controls managements review significant assumptions inputs used estimation medicaid medicare managed care rebates among others including significant assumptions discussed testing inclusive managements controls evaluate accuracy reserve judgments actual rebates paid rebate validation processing controls ensure data used evaluate support significant assumptions complete accurate applicable verified external data sources test sales rebate accruals medicaid medicare managed care programs audit procedures included among others understanding evaluating significant assumptions underlying data used managements calculations testing significant assumptions included corroboration external data sources evaluated reasonableness assumptions light industry economic trends product profiles regulatory factors assessed historical accuracy managements estimates comparing actual activity previous estimates performed analytical procedures based internal external data sources evaluate completeness reserves medicaid involved specialist understanding statutory reimbursement requirements assess consistency companys calculation methodologies applicable government regulations policy valuation contingent consideration description matter discussed note consolidated financial statements caption business combinations note caption financial instruments fair value measures company recognized contingent consideration liabilities estimated fair value acquisition date connection applying acquisition method accounting business combinations subsequent changes fair value contingent consideration liabilities recorded within consolidated statement earnings period change december company million contingent consideration liabilities represented level fair value measurement fair value hierarchy due significant unobservable inputs used determining fair value use management judgment assumptions market participants would use pricing liabilities auditing valuation contingent consideration liabilities complex required significant auditor judgment due use monte carlo simulation model high degree subjectivity evaluating certain assumptions required estimate fair value contingent royalty payments particular fair value measurement sensitive significant assumptions underlying estimated amount future sales acquired products management utilized expertise within industry knowledge clinical development regulatory approval processes determine certain assumptions addressed obtained understanding evaluated design tested operating effectiveness controls companys matter audit contingent consideration liabilities process including among others managements process establish significant assumptions measure liability included testing controls managements review significant assumptions inputs used determination fair value testing inclusive key management review controls monitor evaluate clinical development acquired products estimated future sales controls ensure data used evaluate support significant assumptions complete accurate applicable verified external data sources test estimated fair value contingent consideration liabilities audit procedures included among others inspecting terms executed agreement assessing monte carlo simulation model used testing key contractual inputs significant assumptions discussed evaluated assumptions judgments light observable industry economic trends standards external data sources regulatory factors estimated amounts future sales evaluated reasonableness relation internal external analyses clinical development progress timelines probability success benchmarks regulatory notices procedures included evaluating data sources used management determining assumptions necessary included evaluation available information either corroborated contradicted managements conclusions involved valuation specialist assess companys monte carlo simulation model perform corroborative fair value calculations ernst young llp served companys auditor since chicago illinois february form kitem changes disagreements accountants accounting financial disclosure none item controls procedures disclosure controls procedures internal control financial reporting evaluation disclosure controls procedures chief executive officer richard gonzalez chief financial officer robert michael evaluated effectiveness abbvie 's disclosure controls procedures end period covered report concluded abbvie 's disclosure controls procedures effective ensure information abbvie required disclose reports files submits securities exchange commission securities exchange act recorded processed summarized reported within time periods specified commission 's rules forms ensure information required disclosed abbvie reports files submits securities exchange act accumulated communicated abbvie 's management including principal executive officer principal financial officer appropriate allow timely decisions regarding required disclosure changes internal control financial reporting changes abbvie 's internal control financial reporting defined rule f securities exchange act materially affected reasonably likely materially affect abbvie 's internal control financial reporting quarter ended december inherent limitations effectiveness controls abbvie 's management including chief executive officer chief financial officer expect abbvie 's disclosure controls internal control financial reporting prevent detect errors fraud control system matter well designed operated provide reasonable absolute assurance control system 's objectives met design control system must reflect fact resource constraints benefits controls must considered relative costs inherent limitations control systems evaluation controls provide absolute assurance misstatements due error fraud occur control issues instances fraud detected inherent limitations include realities judgments decisionmaking faulty breakdowns occur simple error mistake controls also circumvented individual acts persons collusion two people management override controls design system controls based part certain assumptions likelihood future events assurance design succeed achieving stated goals potential future conditions projections evaluation controls effectiveness future periods subject risks time controls may become inadequate changes conditions deterioration degree compliance policies procedures management 's annual report internal control financial reporting management abbvie responsible establishing maintaining adequate internal control financial reporting term defined rule af securities exchange act abbvie 's internal control financial reporting designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles united states however internal control systems matter well designed inherent limitations therefore even systems determined effective provide reasonable assurance respect financial statement preparation reporting management assessed effectiveness abbvie 's internal control financial reporting december making assessment management used criteria set forth committee sponsoring organizations treadway commission coso internal controlintegrated framework framework based assessment management concluded abbvie maintained effective internal control financial reporting december based coso criteria effectiveness abbvie 's internal control financial reporting december audited ernst young llp independent registered public accounting firm stated attestation report expresses unqualified opinion effectiveness abbvie 's internal control financial reporting december report independent registered public accounting firm report abbvie 's independent registered public accounting firm related assessment effectiveness internal control financial reporting included form kreport independent registered public accounting firm stockholders board directors abbvie inc opinion internal control financial reporting audited abbvie inc subsidiaries ' internal control financial reporting december based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission framework coso criteria opinion abbvie inc subsidiaries company maintained material respects effective internal control financial reporting december based coso criteria also audited accordance standards public company accounting oversight board united states pcaob consolidated balance sheets abbvie inc subsidiaries december related consolidated statements earnings comprehensive income equity cash flows three years period ended december related notes report dated february expressed unqualified opinion thereon basis opinion company 's management responsible maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting included accompanying management 's annual report internal control financial reporting responsibility express opinion company 's internal control financial reporting based audit public accounting firm registered pcaob required independent respect company accordance us federal securities laws applicable rules regulations securities exchange commission pcaob conducted audit accordance standards pcaob standards require plan perform audit obtain reasonable assurance whether effective internal control financial reporting maintained material respects audit included obtaining understanding internal control financial reporting assessing risk material weakness exists testing evaluating design operating effectiveness internal control based assessed risk performing procedures considered necessary circumstances believe audit provides reasonable basis opinion definition limitations internal control financial reporting company 's internal control financial reporting process designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles company 's internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets company provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company provide reasonable assurance regarding prevention timely detection unauthorized acquisition use disposition company 's assets could material effect financial statements inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate ernst young llp chicago illinois february item b information none form kpart iii item directors executive officers corporate governance incorporated herein reference information concerning director nominees board directors committeescommittees board directors procedure recommendation nomination directors transaction business annual meeting included abbvie inc proxy statement definitive proxy statement filed march also incorporated herein reference text found caption information executive officers abbvie 's code business conduct requires business activities conducted compliance applicable laws regulations ethical principles values directors officers employees abbvie required read understand abide requirements code business conduct applicable abbvie 's code business conduct available corporate governance section abbvie 's investor relations website wwwabbvieinvestorcom waiver code business conduct directors executive officers may made abbvie 's audit committee abbvie disclose amendment waiver provision code conduct principal executive officer principal financial officer principal accounting officer controller persons performing similar functions website within four business days following date amendment waiver addition abbvie disclose waiver code business conduct executive officers directors website abbvie chief ethics compliance officer reports vice chairman external affairs chief legal officer public policy committee chief ethics compliance officer responsible overseeing administering monitoring abbvie 's compliance program item executive compensation material included abbvie inc proxy statement headings director compensation executive compensation compensation committee report incorporated herein reference definitive proxy statement filed march item security ownership certain beneficial owners management related stockholder matters equity compensation plan information following table presents information december abbvie 's equity compensation plans abbvie common stock authorized issuance c number securities remaining number b available securities weighted future issuance issued upon average exercise equity exercise price compensation outstanding outstanding plans excluding options options securities warrants warrants reflected plan category rights rights column equity compensation plans approved security holders equity compensation plans approved security holders total includes shares issuable abbvie 's incentive stock program pursuant awards granted abbott adjusted abbvie awards connection abbvie 's separation abbott weightedaverage exercise price include outstanding restricted stock units restricted stock awards performance shares exercise price excludes shares issuable upon exercise stock options pursuant rights granted stemcentrx equity incentive plan assumed abbvie upon consummation acquisition stemcentrx inc december options remained outstanding plan options weightedaverage exercise price awards granted plan b information concerning security ownership incorporated herein reference material heading securities ownershipsecurities ownership executive officers directors abbvie inc proxy statement definitive proxy statement filed march item certain relationships related transactions director independence material included abbvie inc proxy statement headings board directors committees corporate governance materials procedures approval related person transactions incorporated herein reference definitive proxy statement filed march item principal accounting fees services material included abbvie inc proxy statement headings audit fees nonaudit fees policy audit committee preapproval audit permissible nonaudit services independent registered public accounting firm incorporated herein reference definitive proxy statement filed march form kpart iv item